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1. Introduction
1.1 Plastic surgery
The art of plastic surgery is the restoration of form and function with the resultant
improvement in patient’s quality of life and aesthetic outcome. It often involves the
formation of flaps (a section of living tissue that carries its own blood supply and is
moved from one area of the body to another to repair a deficit of tissues) to reshape
or mold the defect and thus to approximate the original shape.
Plastic surgery has always been a technology-driven surgical discipline, and there
has been a remarkable evolution over the last 25 years with an increased
understanding of anatomy leading to a whole host of new and more reliable flaps.
Meanwhile, a better understanding of the blood supply of the tissues and the
development and maturation of microsurgery have led to the full fruition of anatomic
principles (Mustoe and Han, 1999).
However, restoration without destruction still challenges plastic surgeons. Current
methods for the repair and replacement of diseased tissues meet formidable barriers
in concept, donor scarcity, impairment to the donor site, morbidity and economics.
Projection indicates that the gap between tissue supply and demand will even
continue to widen in the future (Peters et al., 1998).
1.2 Tissue engineering
Major advances in surgery often come from a marriage of basic and clinical sciences.
Tissue engineering may provide an alternative to existing therapies, which would
allow the restoration of function by creating a completely natural tissue substitute,
with the necessary mechanical and metabolic features, in vivo.
Tissue engineering is a relatively new and emerging interdisciplinary field that applies
the knowledge of bioengineering, life sciences, and the clinical sciences towards
solving critical medical problems of tissue loss and organ failure, thus to create
functional substitutes for damaged tissues by combining engineering principles with
life sciences (Patrik et al., 1999) (Nerem, 1992). It involves applying engineering
principles of transport and reaction phenomena as well as methods of analysis
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towards understanding the complex biological processes that occur in tissue
development and repair. Frequently, knowledge of molecular phenomena and
cellular interactions with surface, biochemical, and mechanical environments are
employed. Though still in its experimental stages, the use of tissue engineering to
regenerate organs and tissues has the potential to affect the length and quality of life
for millions.
The essence of tissue engineering is the use of living cells together with either
natural or synthetic extracellular components in the development of implantable parts
or devices to replace the diseased tissue function, result in the growth of functioning
tissue and the eventual integration of such a device into a host.
Investigators have attempted to engineer almost every human tissue by using various
kinds of biomaterials (Mooney and Mikos, 1999). Among them, Integra (Integra
LifeScience, Plainsboro, NJ) is a notable example. Integra ® Dermal Regeneration
Template is a bilayer membrane system for skin replacement. Upon adequate
vascularization of the dermal layer, a thin, meshed layer of epidermal autograft is
placed over the “neodermis”, thereby closing the wound.
However, formation of the neodermis typically takes about 4-6 weeks by clinical
observation (Integra Users Symposium, Dublin, 2000), which seriously limits the
number of patients who can be treated successfully.
1.3 Angiogenesis and growth factors
The kinetics and extent of the neovascularization process, are critical for the survival
and subsequent function of autologous grafts. The same is no less true for any
tissue-engineered substitutes. Engineered tissues more than a few millimeters thick
require blood vessels to grow into them and supply nutrients. A vascular network
must be rapidly formed throughout the new tissue to ensure an adequate supply of
essential elements (e.g., oxygen). This process of generating new microvasculature,
termed angiogenesis, is a process observed physiologically in development and
wound healing.
Angiogenesis is mediated by growth factors, polypeptides that transmit signals to
control cell growth and activity. Growth factors are capable of exerting their influence
at concentrations within the picomole range. The use of growth factors has become
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an important aspect of tissue engineering because it allows modulation of cellular
function and tissue formation at the afflicted site (Lu et al., 2000). With the increased
availability of growth factors derived from cultured human cells and expanded
through recombinant technologies, coupled with an increasing understanding of their
functions and clinical applications, the need for useful pharmaceutical forms is
becoming more and more apparent. Although the applications of growth factors have
the potential to enhance the tissue substitute survival, the delivery of growth factors
poses a major challenge. Controlled studies of their action in research and clinical
work have been hampered, because it is difficult to administer the growth factors
over long periods of time in bioactive form at a physiological dose. Previous efforts at
incorporating growth factors (e.g. basic fibroblast growth factor, bFGF) within a
sustained release vehicle have only been partially successful (Edelman et al., 1991).
1.4 Aim of this study
In this study, we focused on taking collagen sponge as the substance of tissue
substitute. It has been widely reported that biodegradable collagen sponges with a
porous and fibrillar structure can be used as scaffold for wound tissue (Doillon et al.,
1994) (Boyce et al., 1988), because collagen-based materials in the design and
preparation of tissue substitutes offer a high degree of plasticity that is needed to
meet application criteria.
However, as mentioned before, a primary factor which limits engineering tissues of
substantial size is the lack of nutrients of blood supply (Peters et al., 1998). We
suppose that one solution to this limitation is to stimulate the rapid development of a
vascular network within three-dimensional tissue engineering matrices. A variety of
angiogenesis-inducing growth factors have been identified. Among them, vascular
endothelial growth factor (VEGF) is an endothelial cell specific mitogen and a potent
stimulator of angiogenesis in vivo (Peters et al., 1998) (Plate and Warnke, 1997). We
suppose that it might be possible to promote rapid angiogenesis in the implanted
tissue substitute by modulating the local concentration of VEGF. Thus VEGF can
stimulate the endothelial cells, those are already present in the patient's body, to
migrate from the surrounding tissue, to proliferate, and finally differentiate into blood
vessels.
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A major challenge is to achieve a high VEGF loading efficiency sufficient for
prolonged therapeutic effect. To overcome rapid diffusion and clearance from the
implant site and also to increase stability, VEGF is covalently bound to collagen
sponges by means of the homobifunctional cross-linking agent bis-
(succinimidylsuccinate)-polyethyleneglycol (SS-PEG3400-SS; Shearwater Polymers).
Collagen sponges for controlled release are furthermore cross-linked with SS-
PEG3400-SS for slowing down rapid degradation. The biological behavior of collagen
sponges, as well as tissue and cell reactions after the treatment with SS-PEG3400-SS
will be discussed.
In conclusion, the long term aim of the present study is to develop a tissue substitute
that can be used by the plastic surgeons and other specialist. This tissue substitute
should be able to selectively induce a growth factor mediated angeogenic response.
It should help to determine the three-dimensional morphology, to increase cell
survival, to provide initial mechanical stability, to support tissue ingrowth, and to aid
in the formation of tissue structure, and ultimately it should be replaced by a
regenerated extracellular matrix (ECM) to form normal , completely natural tissue.
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2. Research background
2.1 Collagen as a tissue substitute
The success of the tissue substitute is highly dependent on the properties of the
implant material, requiring minimally that it should be biocompatible, easily
sterilizable, and degradable into harmless products that can be metabolized or
excreted. In the search for biomaterials that are versatile and compatible with human
tissues, considerable interest has been maintained in collagen based materials for
repair and replacement of soft body tissues (Babensee et al., 1998).
Collagen represents the chief structural protein accounting for approximately 30% of
all vertebrate body protein. More than 90% of the extracellular protein in the tendon
and bone and more than 50% of the skin consists of collagen. The main function of
collagen is mechanical reinforcement of the connective tissues of vertebrates.
2.1.1 Medical applications of collagen
Collagen is of great interest as a biomaterial because of the following features
(Anselme et al., 1990) (Matton et al., 1985) (Chvapil, 1977):
1. It represents one of the major components of natural extracellular matrices with
low toxicity, low immunogenicity and high biocompatibility which is attributed to the
similarity in the amino acid sequence between species and the low content of
aromatic amino acids
2. It has abundant sources
3. It is a suitable substrate for cell attachment through integrin clusters
4. Its chemotactic effect accelerates infiltration of surrounding cells
5. It affects homeostasis through inducing platelet aggregation
6. It can be biodegraded without toxic byproducts
With the development of processing technology collagen can now be made into
different forms like gels, films, tubes, particles or sponges (Friess, 1998), all of which
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have found use in medical practice, for example as a scaffold for skin, connective
tissue and peripheral nerve tissue engineering. Black et al. (Black et al., 1999) (Black
et al., 1998) seeded fibroblasts with or without endothelial cells onto
collagen/chitosan sponges to construct dermal equivalent. Nehrer et al. (Nehrer et
al., 1997) used porous collagen matrices as a scaffold for cultured chondrocytes to
engineer cartilage and found a marked influence of collagen type and pore
characteristics on the phenotypic expression of seeded chondrocytes. Furthermore,
attempts have been made to apply these forms of collagen as a drug delivery system
in a variety of applications such as in ophthalmology (Rubin et al., 1973), wound and
burn dressing. Friess recently reviewed the use of collagen for delivery of antibiotics,
local anesthetics, steroids, chemotherapeutics, growth factors as well as large
proteins (Friess, 1998). Controlled release of bioactive molecules such as cytokines
and growth factors has become an important aspect of tissue engineering because it
allows modulation of cellular function and tissue formation at the afflicted site (Friess
et al., 1999).
2.1.2 Structure of collagen and natural cross-linking
The individual polypeptide chains of collagen contain all the 20 different amino acids
and the precise composition varies between different tissues. The variation in specific
amino acid sequences which leads to the variation of the length of the helix and the
nature and size of the non-helical portions giving rise to different types of collagen
labeled as Type I, Type II up to Type XIX. Among them, collagen type I is the most
abundant and the majority of collagen materials for biomedical applications are
based on this type (Friess, 1998). Due to these reasons, the paragraph below is
limited to collagen type I.
The name collagen is used as a generic term to cover a wide range of protein
molecules that form supramolecular matrix structures. They share the basic texture
of three individual alpha-helices that are cross-linked biosynthetically and fold to form
a triple helix (tertiary structure) with a molecular weight of approximately 300 kD, a
length of approximately 300 nm and a diameter of 1.5 nm.
This triple-helix generates a symmetrical pattern of three left-handed helical alpha-
chains, which consist of about 1000 amino acid residues. These chains are twisted
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with a distance of 2.91 Å, with a relative angle of –110o, making the number of
residues per turn 3.27 and the distance between each third glycine 8.7 Å. Collagens
are generally characterized by a relatively high content of hydroxylysine and
hydroxyproline. These amino acids are formed post-translationally. The presence of
the cyclic amino acids, Proline (Pro) and Hydroxyproline (Hyp) imparts rigidity and
stability of the coil. Glycine (Gly), the smallest amino acid, must be in every third
position in order to create the right-handed triple helix (Figure 1).
-Gly-Pro-Y-Gly-X-Hyp-
Primary structure Secondary  structure
Tertiary structure quarternary  structure
a) b)
c) d)
Figure 1  The molecular architecture of the fiber forming collagen.
Furthermore, the hydroxyl groups of Hyp residues are involved in hydrogen bonding
and are important for stabilizing the triple-helix structure and two hydrogen bonds per
triplet are found. The two hydrogen bonds formed are: one between the NH-group of
a glycyl residue and the CO-group of the residue in the second position of the triplet
in the adjacent chain, and one via the water molecule participating in the formation of
additional hydrogen bonds with the help of the hydroxyl group of Hyp in the third
position. Such a ‘water-bridged’ model of the triple helix has been confirmed by
physicochemical studies of the collagen molecule in solution and is supported by the
observation that the thermal stability of the helix is dependent on the content of Hyp
and not of Pro. In addition, model studies showed that the Gly, Hyp and Pro are the
triple-helix forming amino acids and that only molecules which contain the triplets
Gly-Pro-Hyp are able to form this special helical structure (Zeeman, 1998a).
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The mechanical and chemical stability of collagen derives from intra- and
intermolecular cross-links. Intramolecular cross-links form between two a-chains of
the non-helical section of the same molecule by aldol condensation of two aldehydes,
which are formed by oxidation of lysyl amnio groups through the action of lysyl
oxidase. Intermolecular cross-links occur between the telopeptide region of one
collagen molecule and the helical region of a quarterly staggered, adjacent molecule.
The bridges between two different tropocollagen molecules result from aldimine
formation between aldehyde residues and e-amino groups presented by lysine and
hydroxylysine. Thus, through specific self-aggregation and cross-linking, collagen
can form fibers with unusual strength and stability (Friess, 1998).
2.1.3 Collagen degradation and exogenous cross-linking of collagen
Collagen is particularly resistant to attacks by neutral proteases, probably due to its
function as the primary structural protein in the body. At neutral pH only specific
collagenases cleave the native helix. Fibrils as aggregates of collagen are degraded
starting from the exterior. Collagenase binds tightly to triple-helices at or near the
surface, whereas molecules in the interior become accessible to enzymes in the
course of the progressive degradation from the outside. After the triple-helix is
cracked, further degradation of the collagen molecules is facilitated by enzymes such
as gelatinases and non-specific proteinases which cleave the primary fragments into
small peptides and amino acids. Elastases and cathepsins assist in degradation
based on their ability to digest non-helical telopeptide regions. Absorption of
exogenous collagen in vivo is therefore a complex multi-enzyme process and it is not
always clear which is the predominant route. Usually the in vivo degradation is
simulated in vitro by incubation with bacterial collagenase, cathepsin, pepsin or
trypsin.
Collagen which did not receive a special treatment degrades immediately. The
biodegradation rate of collagen has to be customized based on the specific
application, in order to maintain the mechanical strength of the transplant and to
avoid collapse or stress shielding (van Wachem et al., 1999) (Zeeman et al., 1999a)
(Zeeman et al., 1999b). For tissue augmentation and drug delivery system an implant
has to maintain its scaffolding properties while it is gradually replaced by host
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collagen, and the degradation rate should be optimized to allow transplanted or
ingrown cells to proliferate and secrete their own extracellular matrix, while the
polymer scaffold can vanish after a desired time period. Thus it is necessary to
introduce exogenous cross-links into the collagen molecular structure.
The homobifuctional agent glutardialdehyde (GDA) has been widely used to cross-
link biomaterials, but it may release toxic components during in vivo biodegradation,
and it may modify the biological properties of collagen (Zeeman et al., 1999) (Doillon
et al., 1994).
2.2 Angiogenesis and Vascular Endothelial Growth Factor (VEGF)
Angiogenesis is controlled through the interaction between soluble growth factors
and insoluble extracellular matrix (ECM) molecules. Soluble mitogens act over long
distances to trigger capillary endothelial cell growth whereas ECM acts locally to
modulate cell sensitivity to these growth stimuli in the local tissue microenvironment
(Ingber et al., 1995) (Ingber and Folkman, 1989).
Investigations by Judah Folkman (Folkman et al., 1979) have shown that cells
already in the body could be coaxed into producing new blood vessels. His work
aimed at the prevention of cellular growth in the form of cancerous tumors, but today
this concept is exploited by tissue engineers: since the engineered tissues as
vascular grafts do not have angiogenic capability by themselves. The introduction of
biological factors could enhance angiogenesis in the prosthesis tissues (Fournier and
Doillon, 1996). For example, exogenous growth factors may be applied to polymers
specifically designed to ultimately yield the most efficacious microenviroment to
optimize the histologic tissue response.
Growth factors can generally be defined as proteins that promote proliferation and
migration of cells, by interaction with specific cell-membrane receptors (Wissink et al.,
2000a). They can either stimulate or inhibit cell division, differentiation, migration or
gene expression, depending on the cells involved (Nimni, 1997). Among them,
Vascular Endothelial Growth Factor (VEGF) plays a central role in the regulation of
vasculogenesis.
VEGF is a potent and specific mitogen for endothelial cells derived from small or
large vessels but is apparently devoid of appreciable mitogenic activity for other cell
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types (Ferrara and Alitalo, 1999) (Neufeld et al., 1999) (Vernon and Sage, 1999)
(Senger et al., 1996) (Keyt et al., 1996). The reported activities of VEGF include
stimulation of endothelial cell growth, angiogenesis, and capillary permeability. VEGF
is synthesized and secreted by many differentiated cells in response to a variety of
stimuli including hypoxia. VEGF is expressed in a variety of tissues as multiple
homodimeric forms (121, 165, 189, and 206 amino acids/monomer) resulting from
alternative RNA splicing (Keyt et al., 1996). Little is known about the regulation of
VEGF isoform expression but these isoforms are not necessarily produced
coordinately. VEGF165 and VEGF121 appear to be the most abundant forms of VEGF
(Klagsbrun and D'Amore, 1996). In our study we focus on the application of VEGF165
since, this variant is up to 100-fold more potent than VEGF121 (Keyt et al., 1996).
Human VEGF165 secreted by a variety of vascularized tissues is a 38.2 KDa
homodimeric protein consisting of two polypeptide chains with 165 amino acids each.
The sequence of VEGF165 is shown in Figure 2.
                                                                                                                  1                                                     11
MNFLLSWVHW SLALLLYLHH AKWSQAAPMA EGGGQNHHEV
1 11 21 31
                      21                                             31                                              41                   51
VKFMDVYQRS YCHPIETLVD IFQEYPDEIE YIFKPSCVPL
41 51 61 71
                       61                                    71                      81    91
MRCGGCCNDE GLECVPTEES NITMQIMRIK PHQGQHIGEM
81 91 101 111
                   101                                    111
SFLQHNKCEC RPKKDRARQE KKSVRGKGKG QKRKRKKSRY
121 131 141 151
                                                   121                                           131                                                141
KSWSVPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ
161 171 181 191
151                                             161        165
LELNERTCRC DKPRR
201 211
Figure 2 Translated sequence of VEGF-gene, amino acids 1-26 represent the signal peptide,
whereas the amino acids 142-165 are removed by alternative splicing from the primary
transcript. The amino acids in the shaded sequence parts form the VEGF165 polypeptide.
VEGF binds to high affinity receptors on endothelial cell surfaces. Two so-called
tyrosine kinase receptors have been shown to be high affinity receptors for VEGF.
They are the 180 kDa fas-like tyrosine kinase (Flt-1) and the 200 kDa kinase insert
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domain-containing receptor (KDR). Of the two tyrosine kinase VEGF receptors, KDR
appears to be the major transducer of the VEGF signal in endothelial cells (Shen et
al., 1998) (Klagsbrun and D'Amore, 1996).
We speculate that it may be possible to promote angiogenesis at the site where the
collagen sponge is implanted by enhancing the local concentration of VEGF. Since
VEGF is the only growth factor known to act solely on endothelial cells (Neufeld et
al., 1999) (Dvorak et al., 1995), it will not stimulate non-endothelial cells, such as the
proliferation of fibroblast, which are suspected to cause scar formation.
A high VEGF loading capacity that is sufficient for attaining a sustained and
controlled VEGF release is desired for attaining an enhanced angiogenesis.
2.3 Controlled release of proteins from various carrier materials
Engineering new tissues utilizing biodegradable polymer matrices as the carrier of
angiogenic growth factors is an attractive approach. And the localized, controlled
delivery of these growth factors from a matrix may allow an enhanced vascularization
of engineered tissues (Gaertner and Offord, 1996) (Cote and Doillon, 1992).
To prolong the effect of protein drugs, many studies are being conducted to control
the release of proteins from various carrier materials:
King and Patrick (King and Patrick, 2000) took Poly(DL-Lactide-co-glycolide)
(PLGA)/polyethylene glycol (PEG) microspheres as the carrier to control delivery of
VEGF or transforming growth factor beta1 (TGF-beta1) (Lu et al., 2000). They
coencapsulated VEGF or TGF-beta1 and bovine serum albumin (BSA) into
microspheres fabricated from PEG and PLGA using a solid-encapsulation/solvent
extraction technique. The microspheres released biologically active VEGF or TGF-
beta1 (King and Patrick, 2000) (Lu et al., 2000) (Peters et al., 1998).
Sano et al. (Sano et al., 1998) took collagen as the carrier of the growth factors and
they used minipellet to retain growth factors in the collagen.
It is known that some growth factors are heparin-binding proteins. Wissink, et al.
(Wissink et al., 2000a) (Wissink et al., 2000b) used N-(3-dimethylaminopropyl)-N'-
ethylcarbodiimide (EDC)/N-Hydroxysuccinimide (NHS) cross-linked and heparin
immobilized collagen as the carrier of basic fibroblast growth factor (bFGF), and
endothelial cells were seeded onto the collagen.
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Sheridan et al. (Sheridan et al., 2000) (Sheridan and Tompkins, 1999) reported that
they developed a gas foaming polymer processing approach that allows the
fabrication of three-dimensional porous matrices from bioabsorbable materials.
Angiogenic factors (e.g., vascular endothelial growth factor) were subsequently
incorporated into matrices during the fabrication process. It has been claimed that the
growth factor is released in a controlled manner and retains over 90% of its
bioactivity.
Peters et al. (Peters et al., 1998) took spherical alginate beads as a means of
delivering biologically functional VEGF at a controlled rate over an extended period of
time.
Kawai et al. (Kawai et al., 2000) incorporated bFGF-impregnated gelatin
microspheres into an artificial dermis for the regeneration of dermis-like tissues. The
radioisotope study revealed that incorporation of bFGF-impregnated gelatin
microspheres prolonged in vivo retention of bFGF in the artificial dermis.
In our study, we aim to develop a drug delivery system that will result in a controlled
VEGF release as a function of time. This VEGF delivery system will improve
angiogenesis, while require fewer and smaller dosages, and cause fewer side
effects.
In general, a controlled release system utilizes a polymer matrix as a rate-controlling
device to deliver the drug in a fixed, predetermined pattern for a desired time period.
Controlled-release polymers offer a number of potential advantages when compared
to present methods of drug administration (i.e. injection, oral ingestion, eye drops,
ointments). These potential advantages include the following; (1) the drug
concentration may be continuously maintained in a therapeutically desirable range;
(2) harmful side effects from systemic administration can be reduced or eliminated by
local administration from a controlled release system; (3) drug administration may be
improved and facilitated in underprivileged areas where good medical supervision is
not available; (4) administration of drugs that have short in vivo half lives may be
greatly facilitated; (5) drug delivery by this method is potentially less expensive and
less wasteful of the drug; (6) the polymer used to deliver the drug can function as the
fill-in material or tissue scaffold at the same time.
In order for the drug to be taken up by the desired part of the body, the drug must
firstly be released from the device. The most common mechanism is diffusion,
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whereby the drug migrates from its initial position in the polymer to the outer surface
and then to the body. It must then diffuse from the surface of the device to the
surrounding environment, and finally it must reach its target. Ideally, the first of these
steps should be rate-limiting so that release is mainly dependent on the device itself.
To be more desirable in most situations, a controlled release in a relative long period
might be achieved by tethering the proteins to the collagen matrices via a specific
linkage strategy: covalent coupling of drugs to collagen sponges.
In our study, we have chosen collagen sponges as the carrier of VEGF, since
collagen is highly biocompatible. Collagen formed into sponges may be used as a
tissue substitute and as a 3-D matrix for tissue regeneration. We coupled VEGF to
collagen sponges by covalent cross-linking. The non-cross-linked VEGF will be
released by diffusion only, while the covalently bound VEGF will be released
simultaneously with the degradation of collagen. We hope that we can control the
degradation process of the collagen sponge by controlling the cross-linking degree of
the collagen, thereby controlling the rate of VEGF release.
2.4 The chemistry of protein coupling by  Disuccinimidyl-Disuccinate
Polyethylene Glycol (SS-PEG3400-SS)
Protein conjugation techniques are dependent on two interrelated chemically reactive
groups: the functional groups present on cross-linking reagents (e.g. SS-PEG3400-SS,
SS = Succinimidyl Succinate) and the functional groups present on the target
molecules (e.g. HRP, VEGF, and collagen). Choosing the correct reagent system
forms the basis for successful chemical modification. A careful understanding of the
structure of the target molecules and a smart choice of functional groups provide the
foundation for the successful use of all modification and conjugation techniques.
2.4.1 The chemistry of functional groups
Every chemical modification or conjugation process involves the reaction of one
functional group with another, resulting in the formation of a covalent bond. In our
study, the reactive groups involved are the amino group of proteins (HRP, VEGF and
collagen), and the SS group of SS-PEG3400-SS.
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2.4.1.1 Amino acids and amino groups
Peptides and proteins are composed of amino acids polymerized together through
the formation of peptide (amide) bonds. The peptide-bonded polymer that forms the
backbone of polypeptide structure is called the alpha-chain. The peptide bonds of the
alpha-chain are rigid planar units formed by the reaction of the alpha-amino group of
one amino acid with the alpha-carboxyl group of another.
The sequence and properties of the amino acid constituents determine protein
structure, reactivity, and function. There are 20 common amino acids found
throughout the nature, each containing an specific side chain of particular chemical
structure, charge, hydrogen bonding capability, hydrophilicity (or hydrophobicity), and
reactivity. The side chains do not participate in polypeptide formation and are thus
free to interact and react with their environment.
Amino acids may be grouped depending on the characteristics of their side chains.
There are seven amino acids that contain aliphatic side chains that are relatively
nonpolar and hydrophobic: glycine, alanine, valine, leucine, isoleucine, methionine,
and proline. There is another group of amino acids which contain relatively polar
constituents and are thus hydrophilic in character.
The most significant amino acids for modification and conjugation purposes are the
ones containing ionizable side chains (Hoffman et al., 2000): e.g. aspartic acid (-
COOH group), glutamic acid (-COOH group), lysine (-NH2 group) (Figure 3).
Reactive groups able to couple with amino group-containing molecules are by far the
most common functional groups present on cross-linking or modification reagents. An
amine-coupling process can be used to conjugate with nearly all protein or peptide
molecules as well as a host of other macromolecules. The primary coupling chemical
reactions for modification of amines proceed by one of two routes: acylation or
alkylation. Most of these reactions are rapid, mild and occur in high yield to give
stable amide or secondary amine bonds.
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NH2
NH2
COOH
? -amino group?-amino group
?  -carboxyl group 
Figure 3 Molecular structure of lysine.
2.4.1.2 N-Hydroxysuccinimide (NHS) ester
N-Hydroxysuccinimide (NHS) reacts with carboxyl groups to form NHS ester
derivatives which may be considered as the most common functional groups for
creating reactive acylating agents. NHS esters were first introduced as reactive ends
of homobifunctional cross-linkers (Lomant and Fairbanks, 1976) (Bragg and Hou,
1975). Today, the majority of commercially available amine-reactive cross-linking or
modification reagents utilize NHS esters.
N
O
O
O
R' N
H
O
R
O
R'
+R NH2 + N
O
O
OH
Amine
Compound
NHS Ester                          Amide Bond              NHS 
Derivative                                                        
Figure 4 Reaction of amine compound with NHS ester derivative.
NHS  ester containing reagents react with nucleophiles thereby releasing N-
Hydroxysuccinimide to form an acylated product. The reaction of such esters with
sulfhydryl or hydroxyl groups, forming thioesters or ester linkages, respectively, does
not yield stable conjugates. These bonds rapidly hydrolyze in aqueous environments.
Histidine side-chain nitrogens of the imidazolyl ring also may be acylated with a NHS
ester reagent, but they also hydrolyze rapidly. The presence of imidazole in reaction
buffers only serves to increase the hydrolysis rate of the active ester. Reaction with
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primary and secondary amines, however, creates stable amide and imide linkages,
respectively, that do not break down so readily (Figure 4). Thus, in protein molecules,
NHS ester couples principally with the N-terminal ? -amino and the ?-amino groups of
lysine side chains (Hermanson, 1996a).
2.4.2 Homobifunctional cross-linker SS-PEG3400-SS
In this work, the covalent immobilization is achieved by using the homobifunctional
cross-linking agent SS-PEG3400-SS (Disuccinimidyl-disuccinate-polyethyleneglycol),
which is one of the derivatives of PEG (Polyethyleneglycol) (Figure 5).
PEG 3400
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O
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 O
O
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O
 O
O
ester bond ester bond
Succinimidylester
Bond
Succinimidylester
Bond
Figure 5 Chemical structure of the homobifunctional cross-linking reagent Disuccinimidyl-
disuccinatepolyethyleneglycol (SS-PEG3400-SS ).
2.4.2.1 Properties of the Poly Ethylene Glycol (PEG): spacer of the
homobifunctional  cross-linker
PEG is a polyether-diol with the general structure OH-(CH2CH2O)n-H. PEG has a
wide range of solubility. It is soluble in most organic solvents as well as in aqueous
solutions.
It has been widely reported that PEG is quite safe to be used in vivo. The biological
activities of PEG-conjugates are typically dominated by the non-PEG part of the
molecule (Dittmann, 1973). For the purpose of modification of peptides and proteins
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the useful molecular weight range is 2,000- 20,000 daltons. The toxicity of PEGs with
molecular weights above 1000 daltons is very low. Extensive toxicity studies on PEG-
4000 showed that this polymer even can be safely administered intravenously in 10%
solution to rats, guinea pigs, rabbits, and monkeys at a dose level of 16 g per kg
body weight (Johnson et al., 1971). It is also reported that when administered
intravenously to humans, PEGs with a molecular weight between 1000 ad 6000 are
readily excreted mainly via the kidney.
Since the first reports by Abuchowski and co-workers in 1977 concerning the
alteration of immunological properties toward BSA that had been modified with PEG
(Abuchowski et al., 1977), the interest in polymer modification of biological molecules
by PEG has grown almost exponentially.
The polymer itself, even with a molecular weight of 5.9? 106, is a very poor
immunogen (Johnson et al., 1971). Because the polymer backbone of PEG is not of
biological origin, its polyether backbone is not degradable by mammalian enzymes.
This property results in a slow degradation of the polymer when used in vivo, thus
extending the half-life of modified substances. PEG modification serves to mask any
molecule to which it is coupled- the “pegylated” molecule being protected from
immediate breakdown or from being complexed and inactivated by immunoglobulins
in the bloodstream.
PEG in solution is a highly mobile molecule that creates a large exclusion volume for
its molecular weight, much larger in fact than proteins of comparable size. Whether in
solution or attached to other insoluble supports or surfaces, PEG has a tendency to
exclude other polymers. This property forms a protein-rejecting region that is
effective in preventing nonspecific protein binding. Thus, PEG-modified molecules
display low immunogenicity, have good resistance to proteolytic digestion, and
survive in the bloodstream for extended periods (Dittmann, 1973) (Abuchowski et al.,
1977). The properties of PEG in solution are especially unusual, frequently displaying
amphiphilic tendencies, having the ability to solubilize in both aqueous and
hydrophobic or organic phases.
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2.4.2.2 Applications of PEG derivatives
PEG coupled to other molecules can be used for altering solubility characteristics in
aqueous or organic solvents to increase the stability of proteins in solution, to
enhance the half-life of substances in vivo, to aid in penetrating cell membranes, to
alter pharmacological properties, and to increase biocompatibility, especially toward
implanted foreign substances (Catalog Shearwater Polymers, 1997).The hydrophilic,
biocompatible nature of PEGs and their mild, well-defined chemistry make them ideal
for coupling or tethering protein molecules to protein molecules or protein molecules
to surface of biomaterial (Abuchowski et al., 1977). Research has shown that use of
PEGs as a cross-linker to bind molecules to other molecules and surfaces provides
highly active materials:
In 1977, Davids, Abuchowski, and co-workers demonstrated that covalent attachment
of PEG to a protein gave minimal loss of activity and rendered the protein non-
immunogenic and non-antigenic, thus imparting greatly increased serum lifetime.
Doillon et al. demonstrated that PEGylation of collagen films and sponges resulted in
improved resistance against enzyme degradation in vitro and in a marked delay of
disappearance in vivo (Doillon et al., 1994a).
Bentz et al. used difunctional PEG derivatives for the immobilization of the growth
factor TGF-beta2 (Transforming Growth Factor-beta2) to injectable collagen and
could demonstrate that covalent binding via PEG potentiated and prolonged in vivo
TGF-beta 2 response and stabilized the TGF in vitro (Bentz et al., 1998).
Covalent attachment of PEG derivatives in the vast majority of cases has been
achieved utilizing amino groups of polypeptide molecules as sites of modification.
The first step in this process is substitution of hydroxyl end-groups of the polymer by
electrophile-containing functional groups. This process is often referred to as
'activation' of PEG molecule. Some of the methods suffer from various disadvantages
such as toxicity. Those shortcomings were overcome by using - difunctional N-
hydroxysuccinimidyl (or NHS) active ester of PEG succinate. This form of activated
PEG was first used for cross-linking of proteins. Due to the reagent’s ease of
preparation and excellent reactivity under mild aqueous conditions it was later
adapted for protein modification and still remains one of the most popular reagents of
this class.
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In our study, we choose SS-PEG3400-SS as the cross-linker of VEGF and collagen.
As a NHS active ester of PEG succinate, it has two identical functional succinimidyl
succinate groups (SS) at both ends and a polyethyleneglycol spacer with a molecular
mass of about 3400 in-between. As we have introduced before, the succinimidyl
esters are characterized by a high reactivity towards NH2  groups which are present
on the surface of most hydrophilic proteins and which usually are provided by lysine
side-chains. Moreover the cross-linker has two ester bonds that tend to hydrolyze
slowly under physiological conditions thereby releasing the cross-linked protein
(Figure 5).
2.4.3 Model protein: Horseradish Peroxidase (HRP)
In order to achieve a high VEGF delivery efficiency, many reaction parameters need
to be investigated. Since VEGF is still too expensive to be used in experiments which
have to be repeated several times, we decided to perform pilot experiments with
horseradish peroxidase (HRP), which is characterized by the advantageous features
outlined below:
1. Low cost.
2. Activity can be easily monitored with high sensitivity (? 10 pg/ml) by 3,3',5,5'-
tetramethylbenzidine (TMB) (Figure 6).
3. HRP has about the same molecular size (44 KDa) as the dimer of VEGF165.
4. HRP is a bioactive enzyme, and can thus serve as a good model for studying the
effect of SS-PEG3400-SS on the bioactivity of VEGF.
The function of HRP includes removal of H2O2, oxidation of toxic reductants,
biosynthesis and degradation of lignin, defense response toward wounding and
metabolism of auxin. These functions might be dependent on each other. HRP
catalytic activity: donor + H2O2 = oxidized donor + 2 H2O. TMB is oxidized during the
enzymatic degradation of H2O2 by horseradish peroxidase.
The oxidized product of TMB has a deep blue color at pH>7. A clear yellow color is
formed after addition of the acidic 2 N H2SO4 which stops the reaction. For detection
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of oxidized TMB, the OD of the yellow color is determined with a spectrometer at 450
nm.
CH3
NH2 NH2
CH3 CH3
CH3
NH NH
CH3
CH3
CH3
CH3
2e- 2H+
HRP
H2O2 2H2O
Figure 6 TMB is oxidized during the enzymatic degradation of H2O2 by horseradish peroxidase
(HRP). The oxidized product of TMB has a deep blue color. A clear yellow color is
formed after addition of the acidic stop solution.
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3. Materials and Methods
3.1 Collagen sponge
Collagen sponges  were prepared according to a directional freeze-drying procedure
to achieve sponges with a uniform porous microstructure (Helmholtz Institute for
Biomedical Engineering, Aachen, Germany). The basic material is a collagen
suspension containing 1.8 wt.-% of type I collagen isolated from bovine skin (Dr.
Suwelack Skin & Health Care AG, Billerbeck, Germany). To adjust the pore size of
the collagen sponge, 3.8 wt.-% acetic acid was added to the basic material resulting
in pH = 2.8. The suspension was then directionally solidified under thermally constant
freezing conditions succeeded by a freeze-drying (Heschel et al., 1996) (Heschel and
Rau, 1997) (Schoof et al., 1998). Thus, collagen sponges with a uniform
microstructure and a defined pore size of 40 µm were prepared for this study (Figure
7). The dimension of the sponges used throughout this study in biochemical
experiments is: 0.5 cm ?  0.5 cm ?  0.25 cm, ca. 2 mg in weight. Collagen sponges
were sterilized with EO (ethylene oxide) for 8 h (Griffith Microscience, Zoetermeer,
The Netherlands). EO sterilized sponges used in this study were subjected to
subsequent aeration for at least 2 months.
Figure 7 Electron-microscopic picture of collagen sponge with defined pore structure. (white &
black bars represent 0,1 mm)
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3.2 Protein coupling to collagen
3.2.1 Step 1: conjugation of protein with SS-PEG3400-SS
In the first-step reaction, or conjugation reaction, HRP (Sigma, St. Louis, USA) or
VEGF (Chemicon International, Temecula, USA) is allowed to react with SS-PEG3400-
SS (Shearwater Polymers, Huntsville, USA) in PBS. One of the two SS groups of the
homobifunctional cross-linker will react with the amino groups of protein and PEG-
modified protein conjugates, (Protein-PEG3400-SS)-conjugates form, while the second
SS group will be still available for the next step reaction with collagen (Figure 8).
The reaction can be described as:
Protein + SS-PEG3400-SS         (Protein-PEG3400-SS)-conjugate
The solution is then added to the sample reservoir of the centricon centrifugal filter
device (Millipore, Bedford, USA, YM 10,000 MW), centrifugated at 5000 * g for 0.5
hour. The non-reacted SS-PEG3400 -SS (about 3500 Da) will pass through the
membrane and the reaction stops (Figure 9). The retentate, which contains the
(protein-PEG3400-SS)-conjugate and the protein which has not reacted with SS-
PEG3400-SS is recovered by a 2-minute centrifugation at 5000 * g.
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Figure 8 In the first reaction, SS-PEG3400 -SS  reacts with protein, (Protein-PEG3400-SS)-
conjugate forms.
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Protein Molecule    SS-PEG 3400-SS
Ultrafiltration
Retentate
Filtrate
Figure 9 After the conjugation reaction, ultrafiltration is performed to remove of the excess SS-
PEG3400 -SS .
3.2.2 Step 2: cross-linking of the (protein-PEG3400-SS)-conjugate to collagen
In the second reaction step, or cross-linking reaction, (protein-PEG3400-SS)-conjugate
reacts with collagen for overnight. By this step the second SS group on the conjugate
may react with the amino group on collagen thus to cross-link the (protein-PEG3400 –
SS)-conjugate to collagen (Figure 10).
The reaction can be described as:
(protein-PEG3400-SS)-conjugate + collagen             protein-PEG3400-collagen
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Figure 10 In the second reaction, the protein-PEG conjugate reacts with collagen which leads to
the covalent immobilization onto collagen.
3.2.3 General experimental procedures
3.2.3.1 Effect of SS-PEG3400 -SS on protein (HRP or VEGF) coupling to collagen
sponge
In order to study the effect of the homobifunctional cross-linker SS-PEG3400 -SS on
coupling proteins to collagen sponge, experiments were performed as outlined in
Table 1.
The experiment group 1 was a control group in which no cross-linker was present. In
experiment group 2 the protein is allowed to react with the cross-linker. After a
certain reaction period the first-step reaction is stopped by ultrafiltration and the
excess cross-linker is removed. The ultrafiltration step is followed by a procedure to
recover the Protein-PEG3400 -SS from the retentate, then the conjugate is added to
collagen sponge.
To correctly quantify the amount of protein immobilized to collagen sponge, an
extensive washing procedure is necessary, after which the non-cross-linked protein
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will be washed out, whereas the cross-linked, and the physically adsorbed protein will
stay in the sponge.
For quantification of HRP or VEGF, collagen sponges are degraded with 0.5 ml
collagenase PBS solution (10 units collagenase, Worthington Biochemical
Corporation, Lakewood, USA) from Clostridium histolyticum at pH 7.2, 37 oC. The
released protein in the solution is then determined with a specific and sensitive
spectrophotometrical procedure (HRP) or with an ELISA assay (VEGF).
In order to achieve optimal protein coupling efficiency, several parameters such as
the effect of reaction pH, reaction temperature, the molar ratio of the cross-linker to
the protein, and the necessity of ultrafiltration were studied by taking HRP as a model
protein (Table 1).
Table 1 General experimental procedure for investigating the coupling of HRP to collagen
sponges with SS-PEG3400-SS.
Experiment group 1 Experiment group 2
HRP (5µg) + +
SS-PEG-SS (20µg) - +
PBS (0,5 ml) + +
Ultrafiltration (10,000MW) + +
Collagen sponge (2mg) + + Second step reaction
Washing procedure + +
Collagenase (10U, 0.25ml) + +
HRP activity test + +
First step reaction
Quantification
3.2.3.2 Effect of SS-PEG3400 -SS on HRP coupling to soluble collagen
The first-step reaction or conjugation reaction was the same as in the experiments
with the collagen sponge. In the second-step reaction, (HRP-PEG3400-SS)-conjugate
and non-cross-linked HRP (if there is any) were added to soluble collagen (Fluka,
Buchs, Switzerland) instead of collagen sponges. To quantify the amount of HRP
immobilized, the second-step reaction was followed by another ultrafiltration step with
a membrane with a different cut off (100,000 MW), the HRP (44 kDa) which did not
couple to collagen will pass the membrane, but the collagen molecule (300 kDa) and
the HRP coupled collagen (? 300 kDa) will stay in the retentate. The HRP coupling
efficiency can be quantified by testing the HRP activity in the retentate and the filtrate
(Table 2).
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Table 2 General experimental procedure for investigating the coupling of HRP to soluble
collagen with SS-PEG3400-SS.
Experiment group 1 Experiment group 2
HRP                         (5µg) + +
SS-PEG-SS             (20µg) - +
Ultrafiltration            (10,000MW) + +
Soluble Collagen     (0.2mg) + +      Second step reaction
Ultrafiltration            (100,000MW) + +
HRP activity test + +
   First step reaction
Quantification
3.2.4 Test of protein cross-linking
3.2.4.1 Determination of HRP by spectrophotometric method
To determine the HRP amount, 10 µl TMB (Merck, Darmstadt, Germany) solution (10
mg TMB in 1 ml Dimethylsulfoxide (DMSO, Merck, Darmstadt, Germany)) and 10 µl
0.3% H2O2 was added into each 1ml sample. The reaction was then stopped with 1
ml 10% H2SO4 15 minutes later. The HRP activity of samples can be quantified by
measuring the absorbance at 450 nm wavelength then comparing the data with the
OD (Optical Density) value of a standard concentration of HRP.
3.2.4.2 Determination of VEGF by Enzyme-linked Immunosorbent Essay
(ELISA)
ChemiKine Human VEGF kit (Chemicon International, Temecula, USA) is a sandwich
enzyme immunoassay (ELISA), which determines the amount of free VEGF. With the
ChemiKine assay system, pre-coated mouse monoclonal antibodies generated
against human VEGF are used to capture human VEGF in a sample.
Simultaneously, biotinylated VEGF specific rabbit polyclonal antibodies detect VEGF
in the sample. With the addition of streptavidin-alkaline phosphatase (which binds to
the biotinylated rabbit anti-human polyclonal cytokine antibody), followed by the
addition of the color generating solution the amount of cytokine is detected. The
standard curve demonstrates a direct relationship between OD and VEGF
concentration. By comparing the OD data of the samples with the standard curve, the
VEGF concentration of the samples can be quantified.
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3.2.4.3 Test of the conjugation reaction: HRP binding to SS-PEG3400 -SS
3.2.4.3.1 Reversed Phase High Performance Liquid Chromatography (RP-
HPLC)
Coupling of SS-PEG3400-SS to HRP was monitored by RP-HPLC (Hewlett-Packard
System 1050, Waldbronn, Germany) experiments performed. To prepare the
samples, HRP 50 µg was allowed to react with SS-PEG3400 -SS 200 µg in 500 µl PBS
solution (pH 7.2) for 10  min, then stop the reaction by ultrafiltration. HRP (50 µg)
dissolved in 500 µl PBS solution was taken as the control. Samples were analyzed
on a water/millipore HPLC system equipped with a 600s controller, 626 quaternary
pump system. After reaction of the proteins with the cross-linkers, samples were
immediately acidified to pH 3.0, diluted with 1 vol of 0.1% trifluoroacetic acid (TFA)
containing an excess of glycine, and fractionated on a Vydac 218TP54, 0.46 * 25 cm,
C18 reverse phase column. Solution A was 0.1% TFA in water, and solvent B was
0.1% TFA in acetonitrile. The column was run at room temperature. At a flow rate of
1ml/min, a two-step gradient with a plateau at 38% and 52% solvent B was applied.
3.2.4.3.2 MALDI-TOF (Matrix Assisted Laser Desorption/Ionization Time-Of-
Flight) spectrometry
Molecular mass determination was performed on a Bruker BiflexTM III Maldi time-of-
flight mass spectrometer (Bruker-Franzen Analytik GmbH, Bremen, Germany)
equipped with a multiprobe gridless delayed extraction ion source and an ion-mirror.
The MALDI-TOF technique operates on the principle that when a temporally and
spacially well defined group of ions of differing mass/charge ratios are subjected to
the applied electric field and allowed to drift in a region of constant electric field, they
will traverse this region in a time which depends upon their mass/charge ratios
(Lennon and Glish, 1997).
For MALDI analysis, HRP (50 µg) was allowed to react with SS-PEG3400-SS (200 µg)
for 10 minutes in 500 µl PBS, pH 7.2. Then the sample was mixed with matrix DHB
(2,5-Dihydroxybenzoic acid) and applied to the sample support for measurement. A
HRP solution (50 µg in 500 µl PBS) was taken as the control.
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3.2.4.3.3 SDS-PAGE (Sodium Dodecyl Sulphate-PolyAcrylamide Gel
Electrophoresis)
Almost all analytical electrophoresis procedures of proteins are carried out in
polyacrylamide gels under conditions that ensure dissociation of proteins into their
individual polypeptide subunits and minimize aggregation. Sodium dodecyl sulphate
(SDS, Boehinger Ingelheim, Germany) is a strongly anionic detergent. The denatured
polypeptides bind SDS and become negatively charged. SDS-polypeptide complexes
migration through polyacrylamide go entirely in accordance with the size of the
polypeptides. SDS-PAGE is carried with a discontinuous buffer system in which the
buffer in the reserviors is of a different pH and ionic strength from the buffer used to
cast the gels. The sample and the stacking gel contains Tris. HCL (pH 6.8), the
resolving gel contains Tris. HCL (pH 8.8), and the upper and lower buffer reserviors
contain Tris-glycine (pH 8.3). All components of the system contain 0.1% SDS. The
ability of discontinuous buffer system to concentrate all of the complexes in the
sample into a very small volume greatly increases the resolution of SDS-PAGE.
To prepare the samples, HRP (500 µg) was allowed to react with SS-PEG3400-SS
(2000 µg) in PBS solution (500 µl, pH 7.2) for 10 minutes, 1 hour or 24 hours, then
the reaction was stopped by ultrafiltration, retentates were recovered and adjusted to
HRP concentration 1mg/ml. Samples were further diluted 1:1 with 2x sample buffer
and incubated in a 50 oC  water bath for 20 minutes. Standard HRP sample was
treated in the same way. Samples were run on a 12% SDS-PAGE gel overnight
(150V).
The gels were stained with Coomasie blue to visualize binding of the HRP to SS-
PEG3400 -SS .
Discontinuous buffer system:
Sample buffer
125 mM Tris-HCL pH 6.8
4% SDS
10% 2-mercaptoethanol
20% glycerol
0.04% bromphenol blue
Running buffer
0.25 m Tris pH 8.3
1% SDS
1.92  M glycine
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3.2.4.4 Test of the cross-linking reaction: (HRP-PEG3400-SS) or (VEGF-
PEG3400 –SS)- conjugate binding to collagen sponges
After the second-step reaction, as shown in the schematic illustration below (Figure
11), there should be free protein (loosely absorbed in the collagen sponge), cross-
linked protein (part of which has been covalently immobilized onto collagen) in the
collagen sponge. To test the covalent coupling efficiency of the protein with collagen
sponge, a washing procedure was used. After reacted with HRP or cross-linked HRP
overnight, the collagen sponge samples were extensively washed with PBS 5-7
times, then the sponges are degraded by collagenase. HRP or VEGF left is thought
to be covalently immobilized.
Protein  molecule   SS-PEG3400-SS
Figure 11 After the second-step reaction, there is free protein, (Protein-PEG3400-SS)-conjugate
(part of which has been covalently immobilized onto collagen) in the collagen sponge.
12% Separating gel
Solution component         Volume (ml)
H2O                                   3.3
29.2% acrylamide and 0.8%
N‘,N‘-Methylenbisacrylamide 4.0
1.5 M Tris-HCL pH 8.8      2.5
10% SDS                          0.1
10%  APS                        0.1
TEMED                             0.008
5% Stacking gel
Solution component         Volume (ml)
H2O 2.7
29.2% acrylamide and 0.8%
N‘,N‘-Methylenbisacrylamide 0.67
1.5 M Tris-HCL pH 8.8 0.5
10% SDS                          0.04
10%  APS                         0.04
TEMED                             0.004
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3.2.4.5 Test of (HRP-PEG3400-SS)-conjugate binding with soluble collagen
To correctly quantify the amount of HRP coupled to soluble collagen, an ultrafiltration
procedure was performed, which will cut off the molecules smaller than 100 kD. The
non-cross-linked HRP and (HRP-PEG3400-SS)-conjugate molecules which did not
couple to the collagen molecule will pass through the membrane into the filtrate,
while the cross-linked or non-cross-linked collagen molecules will stay in the
retentate. The HRP coupling efficiency can thus be quantified by measuring the HRP
activity in the retentate.
3.3 Exogenous cross-linking of collagen
Collagen sponges (0.5 cm ?  0.5 cm ? 0 .25 cm, 2 mg) were soaked in SS-PEG3400-SS
PBS solution with a concentration of 4 mg/ml or 40 mg/ml. The reaction was carried
out  at pH 7.2, room temperature for 1 hour. After cross-linking, the sponges were
immersed in PBS and extensively rinsed with deionized water. Collagen sponges of
the control group were immersed in PBS solution for the same time period and then
washed with deionized water.
3.3.1 Resistance against enzyme degradation
2 mg collagen sponges (0.5 cm ?  0.5 cm ? 0 .25 cm) were treated with 0.25 ml
collagenase (40 U/ml) solution. Specimen were incubated at 37 ?C and observed at
15-min intervals during incubation. The incubation time for complete disappearance
of collagen sponges was considered to correlate to the resistance of the modified
collagen against enzymatic degradation.
3.3.2 Amino group assay
The primary amino group content of the collagen sponge samples was determined
spectrophotometrically (492 nm wavelength) after reaction of primary amine groups
with STDB (Sulfosuccinimidyl-4-O-(4,4‘-dimethoxytrityl) butyrate (Sigma, St. Louis,
USA), and subsequent hydrolysis of the reaction products by HClO4 (Figure 12). The
amount of amino groups and the degree of cross-linking, can be calculated by using
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the equations:
A (mol/l) = (OD-0.01)/0.007;
(A : number of amine groups)
Cross-linking degree (%) = ( A of control group-A of sample) * 100 / (A of control
group).
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Figure 12 The principle of the amino group assay of collagen sponge cross-linking.
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3.4 Determination of HRP or VEGF releases from collagen sponges
Proteins (HRP or VEGF) were coupled to collagen sponges according to the
protocols in 2.2.2, then the collagen sponges were immersed in 0.5 ml diluted
collagenase solution (0.04 U/ml). All samples were maintained at 37 oC with shaking
in a thermoshaker.
At 1-5 days in HRP experiments and at 1-10 days in VEGF experiments, the
collagenase solutions were changed and collected daily, then the samples were
stored at –20 oC for future testing. After all the samples were collected, the HRP or
VEGF amounts were determined.
3.5 Test of cytotoxicity of SS-PEG3400-SS
3.5.1 Cell proliferation assay
Human dermal fibroblasts obtained from skin were cultured in DMEM (Dulbecco’s
Modified Eagle Medium, Life Technologies GmbH, Karlsruhe, Germany)
supplemented with 10% FBS (fetal bovine serum, Life Technologies GmbH,
Karlsruhe, Germany), 0.02 mol/L of L-glutamine, 100 U/ml of penicillin, and 100µg/ml
of streptomycin in a moist atmosphere of 5% CO2 at 37 ºC. The culture medium was
changed every 3 days. At confluence, the cells were removed from the flasks by
trypsinization (0.05% trypsin, 0.02% EDTA salt solution). Cultures at passages 3 to 4
were used for the experiments.
To test the cytotoxic effect of SS-PEG3400-SS , fibroblasts proliferation in SS-PEG3400-
SS solution was tested with a MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide) cell proliferation assay kit (Boehringer, Mannheim, Germany).
SS-PEG3400-SS PBS solution was sterilized by injecting the solution through
sterilization filter (Millipore, Molsheim, France) with a pore size of 0,2 µm.
Fibroblasts were seeded at a concentration of 20000 cells/well in 100 µl DMEM
culture medium (with 10% FBS and antibiotics) containing various amounts of SS-
PEG3400 -SS with the final concentration of 0.1 µg/ml-10000 µg/ml into microtiter
plates (tissue culture grade, 96 wells, flat bottom, Becton Dickinson European HQ,
Belgium). Incubate cell cultures for 24 h at 37 °C and 7.5% CO2. Then 10 µl MTT
(tetrazolium salts) solution (5 mg/ml) was added to each well and incubated for 4
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hours. The yellow MTT can be cleaved into a purple formazan dye only by
metabolically active cells.  After incubation the converted formazan crystals were
solublized in 100 µl 100% isopropanol in 0.1N HCl per well for 12 h. Solublized
formazan dye was spectrophotometrically quantified using an ELISA reader at the
measurement wavelength of 570 nm and the reference wavelength of 690 nm. The
absorbance directly correlates to the metabolic activity and thus correlates to the
number of living cells.
3.5.2 Fibroblast seeding onto collagen sponges
In order to study the effects of collagen cross-linking on the cell-ingrowth behavior,
fibroblasts are seeded onto cross-linked or non-cross-linked collagen sponges.
To prepare the cross-linked collagen sponges, EO sterilized sponges were immersed
in SS-PEG3400-SS solution (400 µg/ml) at pH 7.2, room temperature for 1 hour, then
the collagen sponges were washed extensively with PBS. The sponges just
immersed in PBS were taken as the control.
Collagen sponges pieces (1 cm ?  1 cm ?  0.25 cm) were put into in 6-well plates
(Becton Dickinson European HQ, Erembodegem-Aalst, Belgium) for cell seeding.
Primary fibroblasts isolated from human dermis were cultured in a medium
supplemented with 10% (FBS) and antibiotics (100 IU/ml penicillin and 100µg/ml
streptomycin). Passaged fibroblasts were seeded onto collagen sponges at a cell
density of 2? 105 cells/sponge/well in 150 µl medium. 4 hours after seeding 1.5 ml
medium was added to each well. Small volume seeding medium and delayed
addition of culture media are  to ensure fibroblasts complete seeding onto sponges
instead of the well-plate. Cells were cultured in an incubator at 37?C under a humid
atmosphere in 5% CO2. Culture medium was changed every 3 days.
The specimens were prepared and fixed in 4% phosphate-buffered
paraformaldehyde for 48 hours, then washed, dehydrated in graded alcohol,
embedded in paraffin. Serial 6 µm sections were stained with H&E Method.
3.5.3 Subcutaneous implantation and histological examination
To show the animal tissue reaction towards the cross-linked collagen sponges,
cross-linked and the non-cross-linked collagen sponges were implanted
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subcutaneously in Lewis rats. The cross-linked collagen sponges were prepared
following the protocol mentioned in previous paragraph.
20 male Lewis rats, 200-220 g, received implants of collagen sponge. We used ether
inhalation for induction of anesthesia and pentothal intraperitoneally as the main
anaesthetic. The back of the rats were closely shaved and swabbed with alcohol,
then covered with sterile towels. A midline incision 1 cm long was made in the skin in
the dorsal zone, an extending pocket was dissected bluntly beneath the panniculus
carnosus at the right side (Figure 13), and a square of collagen sponge(1 * 1 * 0,4
cm) was inserted into the pocket without fixation. The skin was closed with
interrupted absorbable sutures (Deknalon, Lübeck, Germany). Rats were sacrificed
at 3,7,14,28,42 days after implantation. The dorsal skin with the attached sponges
and muscles beneath was excised. The specimens were prepared and fixed in 4%
phosphate-buffered paraformaldehyde for 48 hours, then washed, dehydrated in
graded alcohol, embedded in paraffin. Serial 6 µm sections were stained with H&E
Method.
BA
Figure 13 A square of collagen sponge (1 * 1 * 0,4 cm) was inserted into the pocket on the backs
of the rats. (A: SS-PEG3400 -SS cross-linked collagen sponge, B: non-cross-linked
collagen sponge.
Collagen sponges were fixed in 70% ethanol and prepared further for paraffin
section. 8 µm thick slides from every specimen were stained with hematoxylin and
eosin. The haematoxylin component stain the cell nuclei blue-black, with good intra-
nuclear detail, while the eosin stains cell cytoplasm of most connective tissue fiber in
varying shades and intensities of pink and red. The samples were examined under a
light microscope.
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4. Results
4.1 Cross-linking of proteins to collagen
4.1.1 Cross-linking of HRP
The major aim of this thesis is the development of a collagen sponge with
immobilized angiogenic factors for enhancing angio- and vasculogenesis. Thus the
immobilization of proteins within collagen sponges represents an important issue.
One of the possibilities to immobilize proteins is the covalent cross-linking with
bifunctional agents.
In this study we investigated the cross-linking of the VEGF to collagen by using the
bifunctional reagent Disuccinimidyldisuccinatepolyethyleneglycol (SS-PEG3400-SS).
Since VEGF is still very expensive, we took horseradish peroxidase (HRP) as a
model protein. As already mentioned in the introduction (1.5.2) this agent is
characterized by the presence of two succinimidylester groups at both ends. These
groups are responsible for the formation of covalent bonds with available amino
functions in the side-chains of lysines. Furthermore the agent comprises two ester
bonds which will hydrolyze slowly and are therefore – in concert with the degradation
of the collagen - expected to play an important role in the long-term release of the
proteins from the collagen.
4.1.1.1 Coupling of HRP to SS-PEG3400-SS and formation of (HRP-PEG3400-
SS)-conjugate
The efficiency of the covalent coupling of HRP to collagen was investigated by  three
different methods: Reversed Phase-HPLC, MALDI-TOF Mass Spectrometry and
SDS-Polyacrylamidegel electrophoresis (PAGE).
Figure 14 shows the RP-HPLC chromatograms of a series of experiments in which
the coupling of the cross-linking agent to HRP was investigated as a function of time.
In the experiment corresponding to figure 14 A non-modified HRP was injected, the
peak appearing at a retention time of 23 minutes thus represents native HRP. The
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chromatogram of Figure 14 B corresponds to an experiment in which HRP and the
bifunctional agent were allowed to react for 10 minutes. The result of this experiment
strongly suggests that after 10 minutes almost all native HRP-molecules have
disappeared and that instead two new peaks have emerged at 26 and 28 minutes.
These new peaks most likely represent newly formed conjugates of HRP and the
bifunctional agent. One could argue that the peak eluting at 26 minutes represents
the HRP-conjugate with one cross-linking molecule and that the peak eluting at 28
minutes corresponds to a conjugate in which two cross-linking molecules are bound.
This experiment strongly suggests that already after a reaction period of only 10
minutes all HRP-molecules have been conjugated to one or two molecules of the
cross-linker.
Minutes
Figure 14 Reversed Phase-HPLC chromatograms of HRP before (A) and after a 10 minute
reaction of HRP with the bifunctional cross-linking agent SS-PEG3400-SS (B). See
Materials and Methods for details of the reaction and chromatographic procedure.
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The cross-linking was further investigated by the mass-spectrophotomeric method
MALDI-TOF. This technique allows the determination of mass of the conjugates
before and after reaction. MALDI-TOF experiments were performed in order to
determine the molecular mass of HRP and of the (HRP-PEG3400-SS)-conjugate.
Figure 15 (A) and (B) show the molecular mass of HRP (43.4 kD) and of the product
of the reaction between HRP and cross-linker (47.1 kD). Deduced from the latter
molecular mass, we can demonstrate the formation of (HRP-PEG3400-SS)-conjugate.
The reaction parameters are the same as described by the RP-HPLC experiments.
The calculated molecular mass of (HRP-PEG3400-SS)-conjugate (47 kD) is in good
agreement with the mass experimentally determined.
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Figure 15 MALDI-TOF mass spectra of native (non-modified) HRP (A) and of the HRP-PEG3400-
SS-conjugate obtained after a reaction time of 10 minutes. See Materials and Methods
for details of the reaction and mass spectroscopic procedure.
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The efficiency of the coupling between the protein and the coupling agent was further
investigated by SDS-PAGE. The apparent molecular mass of the non-modified HRP
(lane 4) corresponds to the theoretical mass deduced from the biochemical
characteristics of this glycoprotein (mass protein entity: 34 kD; mass carbohydrate
entity: 12 kD). Lanes 1-3 correspond to reaction times from 24 hours to 10 minutes.
The result of lane 3 again confirms that after 10 minutes all HRP-molecules are
already conjugated. The apparent molecular mass of the conjugate is estimated to 48
kD, this mass corresponds to the sum of the masses of the glycoprotein and the
cross-linking molecule. The experiment furthermore shows that longer reaction times
do not lead to conjugates in which more than two cross-linking molecules are bound.
36.5 kD
48.5 kD
58 kD
84 kD
116 kD
 1            2          3         4
5
Figure 16 SDS-Polyacrylamidegel electrophoresis of native HRP and of reaction mixtures of HRP
and SS-PEG3400-SS taken after various reaction times. The following proteins and
protein mixtures were applied: lane 1: HRP-conjugate after a reaction time of 24 h; lane
2: HRP-conjugate after 1 h; lane 3: HRP-conjugate after 10 minutes; lane 4: native (non-
modified) HRP and lane 5: Mixture of marker proteins. See Materials & Methods for
experimental details.
4.1.1.2 Coupling of the (HRP-PEG3400-SS)-conjugate to collagen and the
reaction parameters influencing it
In the previous paragraphs we have demonstrated the formation of (HRP-PEG3400-
SS)-conjugate after the reaction between HRP and SS-PEG3400-SS. In this
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paragraph, we report on the coupling of (HRP-PEG3400-SS)-conjugate to collagen
sponge.
In order to achieve a high efficiency and to study the influence of several parameters
such as temperature, pH, and reaction time, on the coupling reaction between the
(protein-PEG3400-SS)-conjugate and collagen, experiments were performed under
varying conditions.
4.1.1.2.1 Effect of exposure to collagenase, SS-PEG3400-SS and PBS on activity
of HRP
As mentioned in materials and methods, collagenase solution is used in every
experiment to degrade the collagen matrix leading to the release of the immobilized
HRP-PEG3400-conjugate. It is therefore necessary to investigate the effect of
collagenase on HRP activity.  At the same time, it is important to know the effect of
the homobifunctional cross-linker on HRP activity.
Before we investigate the effect of the different parameters on (Protein-PEG3400-SS)-
conjugate coupling efficiency, experiments have been performed to test the influence
of collagenase, SS-PEG3400-SS and PBS on the activity of HRP as a function of time.
The activity of HRP in PBS was taken as a control.
Figure 17 demonstrates that an exposure of 1 hour  to a collagenase containing
solution (40 U/ml) does not have a big impact on the activity of HRP.
Exposure to a SS-PEG3400-SS solution (80 µg/ml), however, leads to a substantial
reduction of the HRP activity. Similar results are obtained when HRP is exposed  for
1 hour to a PBS solution (buffer).
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Figure 17 The activity of HRP after treatment with PBS, SS-PEG3400-SS (80 µg/ml) or collagenase
solution (40 U/ml) for 1 hour. Results shown represent average values. The error bars
are too low to be seen in this experiment (n=4).
The results of Figure 18 show that the activity of HRP (500 pg/ml) decreases as a
function of time after exposure in PBS or SS-PEG3400-SS solution at pH 7.2, room
temperature. After 24 hours, HRP lost most of its activity in PBS, while its activity is
maintained in SS-PEG3400-SS solution (Table 3).
Table 3 Effect of PBS and SS-PEG3400-SS on HRP activity
10 min 1 hour 24 hours
with PBS 1.06±0.007 1.03±0.015 0.325±0
with SS-PEG3400-SS 0.811±0.001 0,87±0.011 0.735±0,001
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Figure 18 The dependency of the HRP activity on exposure to PBS and SS-PEG3400-SS solution
(80 µg/ml) for exposure times varying from 10 min to 24 hours. The concentration of
HRP is 500 pg/ml. Results shown represent average values and error bars represent
the standard deviations (n=4).
4.1.1.2.2 Effect of the conjugation time on the coupling efficiency
In this paragraph the influence of the reaction time of the conjugation of HRP to SS-
PEG3400-SS on the overall efficiency of the coupling of HRP to the collagen was
reported.
Table 4 Effect of the reaction time of the conjugation step (first reaction step) on the overall coupling
efficiency
HRP (5µg)
SS-PEG-SS (20µg)
PBS (0.5ml)
pH
Reaction time
Ultrafiltration
CS (2mg)
HRP immobilized (ng)
+
+
+
7,2 7,2 7,2
24h10 min
+
-
+
7,2
+
+
- + ++
0,623±0,11,023±0,22 14,533±0,4 3,037±0,46
+
+ + +
1h-
Table 4 summarizes a series of experiments in which HRP was allowed to react for
various times (10 min, 1 hour or 24 hours) with the cross-linking agent. The
conjugation reaction was stopped after the given reaction period by ultrafiltration. The
retentates, which contain the HRP-PEG3400-conjugates, were added to the collagen.
The conjugates were allowed to react with the collagen for a fixed period of time (15
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h). The results of HRP coupling (HRP immobilized [ng]) are shown graphically in a
column diagram (Figure19).
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Figure 19 Effect of the reaction time of HRP and SS-PEG3400-SS on HRP coupling. The reaction
conditions are listed in Table 4. Column  heights correspond to the mean values and the
error bars to the standard deviations (n=4).
The results of Figure 19 clearly demonstrate that a reaction time of 10 minutes leads
to the highest amounts of immobilized HRP. Longer reaction times result in lower
coupling efficiencies.
4.1.1.2.3 Effect of conjugation pH on the coupling efficiency
The effect of the pH in the conjugation reaction on the coupling efficiency was
investigated in a series of experiments as explained (shown) in Table 5. The results
at the various pH-values are compared with  the results of control experiments which
were carried out in the absence of the cross-linker. The results of HRP coupling
efficiency (HRP immobilized [ng]) are shown graphically in the column diagram of
Figure 20. Coupling efficiencies are highest at pH 7.2 and 8.5, lower and higher pH-
values lead to lower binding efficiency.
Figure 20 shows that the pH of buffer used in reactions plays an important role in
(HRP-PEG3400-SS)-conjugate coupling process. Figure 20 shows that the coupling
efficiency is optimal at the pH-values 7.2 and 8.5. At more acidic (pH 5.5) or more
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alkaline pH-values (pH 10) the amount of covalently cross-linked HRP is substantially
reduced.
Table 5 Effect of pH on HRP coupling efficiency.
HRP                  (5µg)
SS-PEG-SS     (20µg)
Reaction time
pH
Ultrafiltration
CS (2mg)
HRP immobilized (ng)
5,5 7,2 8,5
+ +
- - -
-
+ +
- - - -
-
- - -
+ + + +
5,5 7,2 8,5 10 10
+
+ + + +
+ + + +
10 min 10 min 10 min 10 min
+ + +
+ + + +
1,42±0,15 1,583±0,62 0,667±0,1 0,90±0,03 1,2±0,13 6,767±0,13 6,667±0,007 3,22±0,18
0
1
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Figure 20 Effect of  the reaction pH of HRP and SS-PEG3400-SS on HRP coupling efficiency.
Column  heights correspond to the mean values and the error bars to the standard
deviations (n=4).
4.1.1.2.4 Effect of conjugation HRP/ SS-PEG 3400-SS molar ratio on the
coupling efficiency
Table 6 summarizes the experimental procedures and the results of a series of
experiments in which the influence of HRP/cross-linker molar ratios on the coupling
efficiency has been investigated. Again the essential results are shown graphically in
the column diagram of Figure 21. Although higher HRP/SS-PEG3400-SS ratios give
rise to higher coupling efficiencies, a molar ratio of 1:50 appears to be optimal.
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Table 6 Effect of HRP/SS-(PEG3400)-SS molar ratio on HRP coupling efficiency.
Molar ratio
HRP (250µl)
SS-PEG-SS (250µl)
HRP immobilized
[ng]
 1:50  1:5001:1
5µg
10,32±0,29
8
5µg
200µg
12,58±3,05
2
0,92±0,14
1
2,12±0,11
2
0,87±0,0
3
5µg
20µg
5µg 5µg
- 2µg0,4µg
1:0  1:5
0,00
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Figure 21 Effect of various HRP/SS-PEG3400-SS molar ratios on HRP coupling efficiency. Column
heights correspond to mean values, error bars to standard deviation (n=4).
4.1.1.2.5 Effect of the ultrafiltration step on the coupling efficiency
In principal the coupling of HRP via conjugation with the bifunctional cross-linking
agent SS-PEG3400-SS can be performed in two ways. In the first procedure the
conjugation reaction is stopped by a ultrafiltration step. In this step the cross-linker
molecules which have not reacted with the protein within the given reaction time are
removed by ultrafiltration through a filter membrane with a cut-off of 10 kDa. In the
second procedure the ultrafiltration step is omitted, this means that in this case in
addition to the conjugate, also  the cross-linker molecules, which have not reacted
with the protein, are given to the collagen sponge. Experimental parameters and
results are summarized in Table 7.
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Table 7 Effect of ultrafiltration on HRP coupling efficiency.
HRP                  (5µg)
SS-PEG-SS (20µg)
pH
Reaction time
Ultrafiltration
CS (2mg)
HRP immobilized (ng)
+
+
-
7,2 7,2
+
-
-
+
10 min-
+
7,2
- +
7,2
-
+
10 min
+ + +
2,75±0,382 1,12±0,08 5,29±2,013 16,25±2,145
+
+
The essential results are also shown in the column diagram of Figure 22. The results
of Figure 22 clearly demonstrate that the ultrafiltration step strongly improves the
coupling efficiency. Apparently the removal of cross-linker molecules, which have not
reacted, has a positive effect on the coupling efficiency. A possible explanation for
this phenomenon will be given in the Discussion.
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Figure 22 Effect of ultrafiltration on HRP coupling efficiency. Column  heights correspond to the
mean values and the error bars to the standard deviations (n=4).
4.1.1.2.6 Effect of conjugation temperature on the coupling efficiency
In this study, the influence of the reaction temperature of the conjugation step on the
coupling efficiency has also been studied. Experimental parameters and results are
shown in Table 8.
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Table 8 Effect of reaction temperature on HRP coupling efficiency.
CS                             (2mg)
HRP                          (250µl)
SS-PEG-SS              (250µl)
Reaction temperature ( oC)
HRP immobilized    [ng]
control, 4oC control, 22oC control, 37oC NHS-PEG-NHS, 4oC
5µg 5µg 5µg
+
NHS-PEG-NHS, 22oC NHS-PEG-NHS, 37oC
22 37
5µg 5µg
+ ++
4
20µg
4 22
20µg
+ +
- - - 20µg
5µg
2,32±0,32 2,52±1,45 2,49±0,7 16,62±4,03
37
16,52±1,67 10,4±1,41
The final results are shown graphically in the column diagram of Figure 23. The
conjugation step was performed at three different temperatures: 4 °C , 22 °C or 37
°C. The coupling efficiencies  at 4 oC and 22 oC are similar, the efficiency at 37 oC,
however, is substantially reduced.
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Figure 23 Effect of the reaction temperature on HRP coupling. Column  heights correspond to the
mean values and the error bars to the standard deviations (n=4).
4.1.1.3 HRP coupling efficiency under optimized conditions
Table 9 reports on a set of coupling experiments which were performed under
optimized conditions. These optimized conditions were deduced from the results of
experiments described in previous paragraphs. These optimized conditions are: pH
of the conjugation reaction 7.2,  protein and cross-linker were allowed to react for
only 10 minutes, the reaction was then stopped by ultrafiltration and the reaction was
performed at room temperature. Under these conditions an 8 times higher amount of
HRP was immobilized in collagen sponges as compared with the group of control
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experiments, which were performed in the absence of the cross-linking agent (Figure
24).
Table 9 General experimental protocol with HRP.
HRP (5µg)
SS-PEG-SS (20µg)
PBS (0.5ml)
pH
Reaction time
Ultrafiltration
CS (2mg)
HRP immobilized (ng)
HRP in the sixth washout ( ng)
+ +
+ +
- +
2,2±0,16 16,8±0,83
7,27,2
+ +
+-
10'-
0,038±0,009 0,099±0,0005
0
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Figure 24 Binding of HRP to collagen sponges in the presence and absence of the SS-PEG3400-
SS. Column  heights correspond to the mean values and the error bars to the
standard deviations (n=4).
4.1.1.4 Coupling of HRP to soluble collagen (with SS-PEG 3400-SS)
Figure 25 shows that by using optimized reaction conditions, pH 7.2, 10’ reaction of
HRP with SS-PEG3400-SS, then followed by ultrafiltration, a 3 times higher HRP
amount was bound to soluble collage than to the control group.
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Figure 25 Effect of SS-PEG3400-SS on HRP coupling to soluble collagen. Column  heights
correspond to the mean values and the error bars to the standard deviations (n=4).
4.1.2 Cross-linking of VEGF to collagen
In the previous paragraphs, HRP was taken as a model protein, and the effect of SS-
PEG3400-SS on HRP coupling to collagen has been demonstrated. In this paragraph,
the effect of SS-PEG3400-SS on VEGF coupling to collagen will be investigated.
Before we study the effect of SS-PEG3400-SS on VEGF coupling, experiments have
been performed to show the influence of SS-PEG3400-SS and collagenase on the
antigenicity of VEGF. Figure 26 shows that the antigenicity of VEGF does not change
obviously in the collagenase solution but was decreased in the SS-PEG3400-SS
solution.
Control
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Figure 26 VEGF standard curves after treatment of VEGF with SS-PEG3400-SS or collagenase for
1 hour. Results shown represent average values and error bars represent the standard
deviations (n=4).
Table 10 summarizes the experimental parameters and results of a series of
experiments in which we investigated the coupling of VEGF to collagen with SS-
PEG3400-SS. The optimal conditions are deduced from the coupling experiments with
HRP (Paragraph 3.1.1.3). The results are shown as column diagram in Figure 27: a
six time higher VEGF coupling efficiency was achieved when compared with the
control group in which the cross-linker was omitted.
Tabel 10 General experimental protocol of VEGF coupling to collagen sponges.
VEGF (0.5µg)
SS-PEG-SS (2µg)
PBS (0.5ml)
pH
Reaction time
Ultrafiltration
CS (2mg)
VEGF immobilized (ng)
+
6,66±0,08
+ +
7,2
10'
+
-
-
+
1,19±0,09
7,2
+ +
- +
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Figure 27 VEGF left after the washing procedure,  the VEGF concentration was determined by
ELISA. Column  heights correspond to the mean values and the error bars to the
standard deviations (n=4).
4.2 Exogenous cross-linking of collagen
As we have mentioned in the introduction, SS-PEG3400-SS  may  also be used to
cross-link the collagen molecules within the collagen sponge. By this procedure
collagen sponges may become more resistant against enzyme attack, leading to
longer degradation time which may be necessary for a controlled release system. In
this part, we investigate the cross-linking of collagen sponges by SS-PEG3400-SS.
4.2.1 In vitro degradation of collagen sponge with collagenase
The in vitro degradation of collagen sponges was studied by exposing the materials
to collagenase from Clostridium histolyticum. As shown in Figure 28, the results show
that when the concentration of the cross-linker was higher than 4mg/ml, the
degradation of SS-PEG3400-SS treated collagen sponges was delayed in comparison
to non-treated collagen sponges.  While strikingly, longer cross-linking times did not
lead to a  longer degradation time.
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Figure 28 Dependence of  the collagenase degradation time from the SS-PEG3400-SS-concen-
tration and the cross-linking reaction time. Column  heights correspond to the mean
values and the error bars to the standard deviations (n=4).
4.2.2 Quantitative determination of colla gen cross-linking
Cross-linking of the collagen using SS-PEG3400-SS results in a decrease of the amino
groups. As shown in Figure 29, collagen sponge cross-linking degree rises as the
increase of SS-PEG3400-SS concentration, but it decreases when reaction lasts
longer which is in good agreement with the results of in vitro degradation
experiments.
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Figure 29 Dependence of  the cross-linking degree from the SS-PEG3400-SS concentration and the
cross-linking reaction time. Column heights correspond to the mean values and the
error bars to the standard deviations (n=4).
4.3 Release of proteins from collagen sponges
4.3.1 Release of HRP
Realizing a controlled release of proteins from collagen sponges represents a major
challenge within the field of tissue engineering and is also is one of the main goals of
this investigation.
Figure 30 compares the release of covalently coupled HRP from non-cross-linked
collagen sponges and collagen sponges cross-linked with SS-PEG3400-SS. The
release is initiated by immersing the sponges into a collagenase containing solution
(0.1U/ml). Both release profiles are characterized by two phases: (a) An initial burst
release occurring during the first 24 hours. The burst observed from the non-cross-
linked collagen sponge was greater (about 95% in 24 hours) than that from the cross-
linked collagen sponge (about 82% in 24 hours). (b) A longer linear steady release
phase that lasts for 5 days. As expected the release of HRP from the cross-linked
collagen sponge was slower.
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Figure 30 Release profiles of cross-linked or non-cross-linked HRP from collagen sponges
degraded with collagenase (0.1 U/ml) at 24-hour intervals. Results shown represent
average values and error bars represent the standard deviations (n=4).
4.3.2 Release of VEGF
The release of VEGF from cross-linked and non-cross-linked collagen sponges is
shown in figure 32. In the control group which was non-cross-linked with SS-PEG3400-
SS, almost all the VEGF released on the first day, and from the second day, VEGF
became undetectable. In the case of the cross-linked sponges VEGF was released
slower, even after 9 days VEGF could still be detected (Figure 31 shows the standard
curve of VEGF).
Results
-58-
y = 0,0006x + 0,554
0
0,5
1
1,5
2
2,5
0 500 1000 1500 2000 2500 3000
Concentration of VEGF [pg/ml]
O
D
 (4
92
nm
)
Figure 31 Standard curve of VEGF
-20,0
0,0
20,0
40,0
60,0
80,0
100,0
120,0
1 2 3 4 5 6 7 8 9 10
Time (days)
V
E
G
F 
re
le
as
ed
 (%
)
VEGF+SS-PEG-SS
VEGF 
Figure 32 Cumulative release of VEGF from collagen sponges with or without treatment of SS-
PEG3400-SS at 24-hour intervals.
4.4 Cytotoxicity tests
Although the cytotoxicity of polyethyleneglycol and a variety of derivatives has
already been investigated, the cytotoxicity of the specific derivative SS-PEG3400-SS
has so far not been tested. It remains  therefore important to demonstrate that also
SS-PEG3400-SS does not induce cytotoxic reactions. Fibroblast cell culture
experiments were performed to study the effect of SS-PEG3400-SS on cells.
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4.4.1 Effect of SS-PEG3400-SS on the proliferation of fibroblasts (MTT- test)
Fibroblasts were cultured in media containing varying concentrations of the cross-
linker (concentration from 0,1 µg/ml to 10 mg/ml). The results as shown in figure 33
clearly demonstrate that according to the MTT-test the cross-linker has no effect on
proliferation of fibroblasts. Only at very high concentrations a minor effect is
observed.
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Figure 33 Proliferation of fibroblast in response to different SS-PEG3400-SS concentration. Results
shown represent average values and error bars represent the standard deviations (n=4).
4.4.2 Effect of SS-PEG3400-SS cross-linking on fibroblast ingrowth into
collagen sponges
Fibroblasts were seeded onto non-cross-linked and cross-linked collagen sponges to
study the response of cells to the cross-linked materials. Results show that
fibroblasts ingrowth was not significantly changed by the cross-linking procedure as
compared to cells ingrown in non-cross-linked collagen sponges (Figure 34, 35).
Figure 34 show that one week after seeding, fibroblasts attached on the surface of
the both groups of collagen sponges with formation of a monolayer of cells covering
the entire sponges surface and the cells began to grow inward. Two weeks after
seeding, histological sections showed that the cells had deeply penetrated into the
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sponges and were  spread over the collagen network (Figure 35). Ingrown fibroblasts
were seen in the center of the sponges, and the cell density or cell morphology
showed no obvious difference between the two groups, suggesting that SS-PEG3400-
SS does not suppress the ingrowth of fibroblasts into collagen sponges.
A
B
Figure  34 Light micrographs showing histological section of collagen sponges seeded with
2x105 fibroblasts/cm2,  1 week after seeding: (A) non-treated collagen sponge; (B)
collagen sponge treated with SS-PEG3400-SS (400 µg/ml). Arrows identify fibroblasts.
Magnification: 200x.
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A
B
Figure  35 Light micrographs showing histological section of collagen sponges seeded with
2x105 fibroblasts/cm2,  2 weeks after seeding: (A) non-treated collagen sponge; (B)
collagen sponge treated with SS-PEG3400-SS (400 µg/ml). Arrows identify fibroblasts.
Magnification: 200x.
4.4.3 Tissue responses to collagen sponge implantation
In order to evaluate the various tissue responses to non-cross-linked or cross-linked
collagen sponges, samples of both types were implanted subcutaneously in rats for
up to 6 weeks. The implanted collagen sponges produced a bulge under the skin,
which disappeared progressively in two weeks, leaving the surface of the skin
absolutely normal. At day 7, all implants were encapsulated by fibrous capsules, in
which capillaries, fibroblasts and inflammation cells were observed. It was also noted
that the capsules of the non-cross-linked collagen sponges were thicker than those of
the cross-linked collagen sponges. Few polymorphonuclear cells (PMN) infiltrated the
implants. One week after implantation, mononuclear cells had replaced the PMN
within the implanted collagen sponges. Newly formed capillaries were observed 2
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weeks after implantation in the center part of both non-cross-linked (Figure 36A) and
cross-linked collagen sponges (Figure 36B). The non-cross-linked sponges began to
collapse 2 weeks after implantation (Figure 37A). The pore structure of the cross-
linked sponges, however, remained intact for at least 4 weeks (Figure 37B).
Accumulation of giant cells was observed close to the collagen/tissue interface, their
number was, however, smaller in the case of the cross-linked collagen sponges
(Figure 38 AB). A larger fibroblast ingrowth and an increase of the deposition of the
extracellular matrix material was observed in the non-cross-linked collagen sponges
(Figure 38 A).
A
B
Figure 36 Collagen sponges after 2 weeks of subcutaneous  implantation.
(A) non-treated collagen sponge; (B) collagen sponge treated with SS-PEG3400-SS (400
µg/ml). Arrows identify ingrown vessels. Magnification: 50x.
Results
-63-
A
B
Figure 37 Collagen sponges: (A) 2 weeks after subcutaneous implantation, non-treated collagen
sponge; (B) 4 weeks after subcutaneous implantation, collagen sponge treated with
SS-PEG3400-SS (400 µg/ml). Magnification: 50x.
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A
B
Figure 38 Collagen sponges at week 4 after implantation.
(A) non-treated collagen sponge. Circles identify angiogenesis, arrows identify foreign
body giant cells; (B) collagen sponge treated with SS-PEG3400-SS (400 µg/ml). Arrows
identify original collagen sponge structure. Magnification: 50x.
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5. Discussion:
Traumatic injuries are often associated with tissue loss. Restoration of normal
structure and function in these cases requires replacement of missing tissue which
may be accomplished by surgical transfer of healthy and natural tissue from an
uninjured location elsewhere in the body (Kaihara and Vacanti, 1999) (Peter et al.,
1998). However, this method is seriously limited by tissue availability and secondary
deformities at the donor site.
To overcome the limitations of the conventional reconstructive approaches, our
objective was to develop a tissue substitute based on biodegradable collagen
matrices. This study aims at an increased ingrowth of cells (e.g., endothelial cells,
fibroblasts) from the host bed into this optimized tissue substitute. These cells should
attach to the seeded scaffold, replicate, differentiate, and organize into normal
healthy tissue as the scaffold degrades.
The crucial point for any cells to replicate and to proliferate is vascularization. This
study demonstrates possible avenues for optimizing matrices via enhancing
vascularization by chemical coupling  of growth factors into the matrix.
A variety of tissue-inducing factors (e.g., growth factors) that promote cell
proliferation have been identified (Nimni, 1997). Among them, growth factors such as
TGF-ß, EGF (epidermal growth factor) and bone morphogenetic proteins (BMP) have
been used with collagen to induce and to promote tissue repair and remolding (Bentz
et al., 1998) (Kuhl and Griffith-Cima, 1996) (Bentz et al., 1991).
The present study focus on the delivery of VEGF,   a potent stimulator of
angiogenesis in vivo which acts specifically on endothelial cells (Neufeld et al., 1999)
(Peters et al., 1998) (Plate and Warnke, 1997) (Klagsbrun and D'Amore, 1996)
(Senger et al., 1996) (Dvorak et al., 1995).
Cell responses to growth factor do not only depend on the presence of the factor, but
on the magnitude and duration of its presence as well (Marshall, 1995). However, if
the growth factors are simply mixed to the collagen matrices, they elicit a ‘burst
release’ because of diffusive spread, cell uptake, and degradation (Bentz et al.,
1998) (Kuhl and Griffith-Cima, 1996). A burst release of growth factor may increase
the local drug concentration to an undesirably high level or at least lead to the loss of
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the excess drug. A controlled release of VEGF is desirable in order to maintain the
released VEGF at an optimally effective concentration.
These problems might be overcome if VEGF is covalently bound to collagen
matrices. In this study, in order to control the release of VEGF and to prolong its
bioactivity, VEGF was covalently linked to collagen sponges via the homobifunctional
cross-linking agent bis-(succinimidyl succinate) polyethylene glycol (SS-PEG3400-SS).
PEG derivatives have been widely used to modify enzymes and growth factors
(Zalipsky et al., 1992) (Katre et al., 1987) (Abuchowski et al., 1977) (Abuchowski et
al., 1977), as well as cross-linking collagen (Catalog Shearwater Polymers, 1997)
(Doillon et al., 1994). Moreover PEG-attached proteins are typically more stable and
usually remain highly active (Katre et al., 1987).
In the present study, the experimental parameters of protein coupling, biological
behavior of collagen sponges as well as tissue and cell reactions after the treatment
of collagen with SS-PEG3400-SS have been investigated.
5.1 Cross-linking of proteins to collagen
To achieve the optimal reaction conditions which will lead to a high VEGF coupling
efficiency, a large number of experiments had to be performed. However, VEGF is
still too expensive to be used for that purpose (500 DM per 10 µg, Chemicon).
HRP has a similar molecular mass as VEGF and its activity can be easily quantified
(Internet protein databank SWISS-PROT, http://www.expasy.ch/cgi-
bin/niceprot.pl?P80679). Due to these reasons, we selected HRP as a model protein.
The coupling or cross-linking procedure was divided into two steps.
In the first step (conjugation reaction), the target protein (VEGF or HRP) was allowed
to react with the homobifunctional cross-linker (SS-PEG3400-SS) and the protein-
PEG-SS-conjugate is formed (Figure 8). In the second step, after stopping the
conjugation reaction via an ultrafiltration procedure (figure 9), the protein-PEG-SS
conjugate is collected and added to collagen sponge in order to realize the covalent
coupling (Figure 10).
Discussion
-67-
One-step or two-step reaction:
Even for our purpose it is tempting to just add all reagents (SS-PEG3400-SS, HRP or
VEGF and collagen sponge) at the same time. Comparing the easy one-step reaction
with the two step procedure in which the first reaction (HRP and PEG) was stopped
by ultrafiltration, the one-step procedure shows a 60% less coupling efficiency.
(Figure 22).
The necessity of a two step procedure was very well discussed by Hermanson
(Hermanson, 1996b). After the conjugation reaction procedure, if the excess cross-
linker molecules have not been removed by the ultrafiltration procedure, they might
competitively block most of the amino groups in collagen during the cross-linking
reaction procedure because of their amount advantage compared to (Protein-
PEG3400-SS)-conjugates, while the amino groups are expected to react with HRP or
VEGF conjugates.
At the same time, the problems of indeterminate conjugation products are amplified
in single-step reaction procedures using homobifunctional reagents (Hermanson,
1996b). Only a small percentage of which represent the desired or optimal conjugate.
Excessive conjugation may cause the formation of insoluble complexes that consist
of very high molecular weight polymers which have no biological activity (Figure 39).
To overcome this shortcoming, a two-step reaction procedure has been used. In the
two-step protocols, HRP or VEGF reacts with SS-PEG3400-SS, the excess cross-
linking reagent and by-products are removed. In the second stage, the activated
protein is mixed with the other protein or molecule to be conjugated, and the final
cross-linking process occurs.
The use of homobifunctional reagents in two-step protocols still creates many of the
problems associated with single-step procedures (Hermanson, 1996a; Hermanson,
1996b). Homobifunctional reagents by definition have the same reactive group on
either end of the cross-linking molecule, the first protein can cross-link and
polymerize with itself long before the second protein is added. This inherent potential
to polymerize uncontrollably is characteristic of all homobifunctional reagents, even in
multi-step protocols.
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Conjugation reaction (first step):
In order to standardize our method several basic experiments were performed. Firstly
the following steps have to be cleared.
?  How long will the conjugation reaction last?
?  How much of the protein will react with SS-PEG3400-SS?
?  Which kinds of products will be formed?
In a series of experiments methods as RP-HPLC, MALDI-TOF and SDS-PAGE have
been used. The results suggest that already after 10 minutes, all HRP molecules
have been reacted with cross-linker molecules.
This was demonstrated by: i) RP-HPLC: after the ten-minute reaction, the peak
appearing at 23 minutes which corresponds to original HRP completely disappeared,
and there are new peaks appearing at 26 and 28 minutes respectively (Figure 14). ii)
MALDI-TOF: after the ten minute reaction, the newly formed product has a molecular
mass of 47 kD rather than 44 kD of the HRP molecule (Figure 15). iii) SDS-PAGE:
after a reaction lasting longer than 10 minutes, only one band appears at about 48 kD
while native HRP migrates corresponding to the expected molecular size of
approximately 44 kD. (Figure 16).
We know from the HRP amino acid sequence that there are altogether 9 lysines in 1
HRP molecule (Internet protein databank SWISS-PROT, http://www.expasy.ch/cgi-
bin/niceprot.pl?P80679). If all the lysines react with SS-PEG3400-SS, the molecular
weight of the newly formed molecule should be around 100 kD. The results of
MALDI-TOF and SDS-PAGE suggest that the molecular mass of the (HRP-PEG3400-
SS)-conjugate is only 47 kD to 48 kD, which means that only 1 SS-PEG3400-SS
molecule has reacted with one HRP molecule. A possible explanation for this
observation may be that many lysine residues are involved in the dimer formation
and not accesible for conjugation.
After the reaction of HRP and SS-PEG3400-SS, there is no band or peak which
corresponds to the original HRP that can be observed in SDS-PAGE or RP-HPLC
experiments respectively. This suggests that the efficiency of the first reaction step is
high. These data are in good agreement with the results of Bentz et al. which also
showed an high combination rate of TGF-ß with the bifunctional cross-linkers
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(difunctional succinimidyl glutarate (D-SG-PEG) or succinimidyl protionate
polyethylene glycol (D-SE-PEG)) (Bentz et al., 1998).
Coupling reaction (second step):
Coupling of the (HRP-PEG3400-SS)-conjugate to collagen sponges was demonstrated
by testing the HRP activity after extracting the non-coupled HRP from collagen
sponges. After the extensive washing procedure, most of the HRP molecules which
have not been coupled to the collagen sponges, were washed out. While the HRP
molecules covalently coupled to collagen and the HRP molecules, which were
physically absorbed, remained in the collagen sponges. The amount of residual HRP
activity was quantified after degrading the collagen sponge with collagenase.
As shown in Figure 24, in both control (only HRP) and (HRP-PEG3400-SS)-conjugate
treated groups, the HRP activity in the last (sixth) washout liquid was almost zero,
demonstrating that most of the physically absorbed HRP was washed out. The
residual HRP activity in the (HRP-PEG3400-SS)-conjugate treated groups was about 8
times higher than that in the control group. These results do demonstrate the effect of
SS-PEG3400-SS in HRP cross-linking to collagen.
The results of our preliminary experiments showed that different reaction conditions
would lead to different final HRP coupling efficiencies. In order to achieve the optimal
reaction conditions that can lead to a higher protein coupling efficiency, we performed
a series of experiments in which we investigated :
?  reaction time of conjugation step,
?  pH,
?  molar ratio of the protein and the cross-linker,
?  ultrafiltration,
?  reaction temperature.
Reaction time:
As the stability of HRP alters with time, the natural deterioration time of HRP and the
effect of the homobifunctional cross-linker on it were determined. HRP was allowed
to react with SS-PEG3400-SS for 10 minutes, 1 hour or 24 hours, then the activity was
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measured and compared with the HRP control groups in which SS-PEG3400-SS was
absent. The results (Figure 18) show that HRP loses its activity as a function of time,
but the trend was slower in the group treated with SS-PEG3400-SS than in the control
group. These data are in good agreement with the results of other researchers’ which
showed that PEG coupled to proteins can increase their stability in solution (Berger
and Pizzo, 1988). This may be explained by the fact that PEG is an uncharged
hydrophilic polymer and typically increases solubility and stability of molecules to
which it is attached (Bentz et al., 1998).
Interestingly the experiments also demonstrate that the HRP coupling efficiency to
collagen is obviously higher in the group in which the first step reaction lasted 10
minutes than in the groups were the reaction lasted longer than 1 hour (Figure 19).
There are two possible explanations for this phenomenon.
One possibility was discussed by Avrameas et al. This group postulated that, it was
possible that the cross-linking of two proteins with homobifunctional agents results in
a system of interconnected conjugates (Avrameas, 1969).
In the first reaction step, the SS-PEG3400-SS may initially react with one of the
proteins, forming an active intermediate. This activated protein may then form cross-
links with other proteins. The activated groups may also react intramolecularly with
other functional groups on the same polypeptide chain (Hermanson, 1996b). As
shown in figure 39, other cross-linker molecules may continue to react with these
already conjugated species to form various mixed products. At longer reaction times,
the HRP conjugates may even react with each other, leading to high molecular
aggregates. Thus even before they have a chance to react with collagen, their
activity would already have been lost.
These aggregates then should have a high molecular mass. However, our SDS-
PAGE results do not support this explanation. After a reaction time of 24 hours, only
one band with an apparent molecular mass of about 48 kDa was observed. This
corresponds to the expected mass of a (HRP-PEG3400-SS)-conjugate. No band
corresponding to the HRP-dimer (about 90 kD) or -trimer  (about 140 kD) has been
observed.
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SS-PEG 3400 -SS
Hydrolyzed  SS
Collagen sponge
Figure 39 The possible reaction products after the first reaction step.
The second possibility is that after a longer reaction time, most activity of the second
functional SS-group on the (HRP-SS3400-SS)-conjugate has been hydrolyzed which is
supposed to react with lysines in collagen sponge in the second step reaction. It is
known that the hydrolysis half life of SS group at pH 8, 25 ºC is 9.8 minutes (Catalog
Shearwater Polymers, 1997), which means that after the ten-minute conjugation
reaction of SS-PEG3400-SS with HRP, half of SS ester groups that are expected to
react with amino groups in collagen, have been lost (Figure 40). If the reaction lasts
longer, the residual activity of SS groups will be even smaller. This may explain why
the coupling efficiency of the HRP-PEG conjugate to the collagen was relativly low.
 SS-PEG
3400
-SS
   Protein
   Hydrolyzed SS
Figure 40 The possible reaction products after the first step reaction.
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Effect of pH:
The pH plays an important role in the coupling procedure (Catalog Shearwater
Polymers, 1997). HRP coupling efficiency is much higher if the pH range is between
7.2 and 8.5 (Fig. 20).
In order to explain this phenomenon we may consider the fact that ionizable amino
groups within proteins can exist in two forms: protonated (NH3+) or unprotonated
(NH2). As shown in figure 8, SS groups of the homobifunctional cross-linker react
with the nucleophilic nonprotonated free amino groups (NH2) of lysine in HRP or
VEGF (in the conjugation reaction) and collagen (in the cross-linking reaction). To
increase the reaction of SS groups with proteins, it is required to convert the free
amino groups in proteins into a more strongly nucleophilic agent or to increase the
molar proportion of non-protonated to protonated amino groups ([R-NH2]/[R-NH3+]).
Increasing the pH of the reaction leads to a higher ratio of [R-NH2]/[R-NH3+] (Sung et
al., 2000), thus the number of non-protonated groups will increase with pH.
Anyhow further increment of the pH results in a higher hydrolysis rate of the
succinimidylesterbond (Lomant and Fairbanks, 1976), this means that a balance has
to be found between the rate of covalent bond formation and hydrolysis.
Temperature:
It is known that the pK values of the ionizable groups in proteins decrease with
increasing temperature (White et al., 1973) (McClain and Wiley, 1972). It can
therefore be deduced that at the same pH the ratio of [R-NH2]/[R-NH3+] increases
with increasing temperature. Thus at higher temperatures the molecules are more
reactive than at lower temperatures, the collision frequency increases, so a higher
combination rate may be expected at a higher temperature. But as indicated in
Figure 23, the HRP combination rate was lower at 37 °C than at 22 °C or 4 °C. This
may be explained by the increased instability of SS-PEG3400-SS at 37 °C than at 4 °C
or 22 °C.
Molar ratio:
In the conjugation reaction procedure, excess amount of SS-PEG3400-SS should be
used. The half-life of SS-PEG3400-SS is relatively short, and some of the reactive
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groups--SS groups will be hydrolyzed even before they can have a chance to react
with HRP or VEGF molecules (Figure 40). We know from the amino acid sequence
that there are 24 lysines in one VEGF (Internet protein databank SWISS-PROT,
http://www.expasy.ch/cgi-bin/niceprot.pl?P15692) and 18 lysines in one HRP
molecule (Internet protein databank SWISS-PROT, http://www.expasy.ch/cgi-
bin/niceprot.pl?P80679) which means every molecule of HRP and VEGF has the
potential to react with several SS-PEG3400-SS molecules. It might be possible to
enhance the protein coupling efficiency by raising the number of SS-PEG3400-SS
molecules coupled to the protein. Our results show that within a certain range HRP
coupling efficiency increases with the increase of the molar ratio of HRP to SS-
PEG3400-SS (Figure 21).
However when too many cross-linker molecules are involved, the active center of the
protein may be blocked. We found that HRP activity decreases with increasing the
concentration of SS-PEG3400-SS. So it appeared to be necessary to adjust the molar
ratio of SS-PEG3400-SS to the target molecule, HRP or VEGF. The level of
modification and conjugation may thus be controlled in order to create an optimal
product.
Soluble collagen:
In the present study, the protein coupling reaction was also investigated by using
soluble collagen. In the experiments that soluble collagen instead of collagen
sponges were used for the second reaction, a much higher HRP collagen coupling
efficiency has been achieved(Figure. 25).
The collagen sponges we use in the experiments are three-dimensional matrices that
have the size of 0,5 * 0,5 * 0,2 cm. The solid three dimensional structure of collagen
sponge may be the limitation of the reaction of HRP or VEGF conjugates within the
center of the collagen sponge, since it may produce a physical barrier for the HRP- or
VEGF-conjugates.
Prolonged penetration time of the HRP- or VEGF-conjugates into the sponge might
result in an activity loss of the second SS groups on the protein conjugates. So it is
possible that there is a concentration gradient of HRP or VEGF conjugates covalently
combined throughout the collagen sponges. And this may be another important
reason for the low protein coupling efficiency besides the short half-life of SS ester.
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This problem can be partly solved by using soluble instead of fibril collagen (Figure
25). If the (HRP-PEG3400-SS)-conjugate is allowed to react with soluble collagen
instead of a collagen sponge the collagen molecules have more chances to collide
with the conjugate-molecules than in the solid collagen sponge.
To transform this protein coupled soluble collagen into collagen sponge in order to
provide a matrix for tissue engineering is base of a current project.
Bioactivity of proteins:
The goal of most protein modification or conjugation procedures is to create a stable
product with good preservation of the native state and activity. Ideally, any
derivatization should result in a protein that performs exactly as it would in its
unmodified original form.
One of the best ways to ensure preserve of the activity in protein molecules is to
avoid chemical reaction at the active center (Hoffman et al., 2000) (Ding et al., 1998).
The active center is the portion of the protein where ligand, antigen, or substrate
binding occurs. The interplay of amino acid functional groups and the three-
dimensional folding of polypeptide chains is seen as the formation process of the
protein activity. It is very important to avoid the active site by selecting functional
groups away from that area or by protecting the site through the incorporation of
additives.
Our results show that SS-PEG3400-SS does not obviously affect the activity of HRP
(Figure 17) or the antigenicity of VEGF (Figure 26) during the cross-linking process.
By checking the amino acid sequence (Internet protein databank: SWISS-PROT,
http://www.expasy.ch/cgi-bin/niceprot.pl?P15692), we know that there are  24 lysines
existing in the dimer molecule of VEGF165 (Figure 41). As shown in Figure 42, only
lys84 is involved in the binding site of the kinase domain receptor (KDR) (Muller et al.,
1997).
We assume that the harmful effect of the bifunctional cross-linker on VEGF bioactivity
can be minimized  by adjusting the molar ratio of VEGF and SS-PEG3400-SS. Further
experiments of our research group will focus on the effects of SS-PEG3400-SS on the
bioactivity of VEGF.
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1                   11                                            21                                        31                               41
APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS
51                                         61                                           71                                       81                                        91
CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEM SFLQHN
101                                     111                                          121                                     131                                      141
KCECRPKKDR ARQEKPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ
151                                     161        165
LELNERTCRC DKPRR
 Figure 41 Amino acids sequence shows the position of lysines (red) in a VEGF165-monomer.
Sequence 8-109 (underlined) was over-expressed to solve the crystal structure shown
in Figure 41.
Pro 85
Lys 84
Ile 43
Ile 46
Glu 64
Arg 82
Met 94
Glu 93 Met 18 Tyr 21
Gln 32
Tyr 25
Figure 42 Main-chain representation of the binding determinants on the structure of VEGF 8–
109 including the side chains of the binding determinates for KDR (blue) and both
antibodies (red for A4.6.1 and yellow for 3.2E3.1.1). This figure was produced using
the software program Raswin.
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5.2 Exogenous cross-linking of collagen for obtaining controlled
degradation
Collagen sponges used as connective tissue scaffold and VEGF carrier must
maintain structural integrity and porosity to facilitate tissue ingrowth. Growth factors
should be incorporated in a stable manner, and released in a controlled manner with
desirable kinetics, thus to promote the vascularization of the developing tissue.
After implantation the collagen sponge is prone to an enzymatic attack which can
result in rapid degradation of the material (Doillon et al., 1994a) (Doillon et al.,
1994b). Therefore collagen sponges used as VEGF carrier should be stabilized by
cross-linking to control the rate of biodegradation.
Our way to couple a growth factor into the sponge has a perfect side effect to this
problem. The used linking agent acts as a cross linker on the collagen microstructure
as well. In this matter cross-linking means the creation of new additional chemical
bonds between the collagen molecules, and thereby reinforce the tissue to give a
tough and strong but non-viable material that maintains the original shape of the
tissue (Figure 43).
The reaction involved during cross-linking have been extensively studied, but the
reaction mechanism is very complex and still not completely understood (Zeeman,
1998b).
One way to investigate the effect is the degradation of the manipulated sponges. The
resistance against enzymatic degradation of the cross-linked or non-cross-linked
collagen sponge is usually studied by in vitro tests (Zeeman et al., 1999a) (Zeeman
et al., 1999b) (Zeeman, 1998a) (Doillon et al., 1994a), using enzymes such as
bacterial collagenase from Clostridium histolyticum, which is capable of cleaving
peptide bonds within the triple helical structure and has a specificity for the Pro-X-
Gly-Pro-Y region, splitting between X and Gly (Friess, 1998). The rate of degradation
of collagen sponge by collagenase is determined by the cross-link density, the
accessibility of the cleavage sites and the extent of denaturation. Cross-links will
hinder the collagenase to act at the specific cleavage sites, thus to decrease the
degradation rate (Zeeman, 1998a). On the other hand, the stability of the PEG-
modified collagen sponges might be linked to the repulsive properties of PEGs after
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which their covalent binding to the amino groups of the protein stabilize the tertiary
structure of the proteins (Doillon et al., 1994a).
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Figure 43 Presumable cross-linking mechanism of collagen with SS-PEG3400-SS.
Our results show that modified collagen sponges have demonstrated a significant
increased biostability. The resistance to collagen degradation rises when the
concentration of SS-PEG3400-SS is increased higher than 40mg/ml (Figure 28). In the
groups where the concentration of SS-PEG3400-SS was lower than 40mg/ml, the
collagen degradation time did not show differences when compared with the control
group.
The free amino group content decreases as the SS-PEG3400-SS concentration rises
(Figure 29). Both the collagen degradation period and degree of cross-linking get
lower when the reactions last longer, which indicates that the cross-linking of the
collagen sponges by SS-PEG3400-SS is completed after about 10 minutes. This
finding is reproducible but the reason for this phenomenon remains unclear. One
might speculate that the high activity of SS group leads to a quick reaction with lysine
groups, and the SS groups will be hydrolyzed in a short time. At the same time, the
cross-linking reaction might be hindered by the 3D structure of the sponges which
may be a physical barrier for the reagents to enter the center part of the sponge, as
discussed earlier.
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5.3 Release of proteins from collagen sponge
Protein drug releasing profiles can be affected by several factors: the hydrophobicity,
size and concentration of the drugs, the interaction with collagen, the pore size and
degradability of the collagen sponge (Peters et al., 1998) (Friess, 1998) (Bentz et al.,
1998). Constant release is desirable in order to maintain the released drug at a
constant effective concentration. A large burst release may increase the local drug
concentration to an undesirably high level or simply lead to the loss of the excess
drug (Peters et al., 1998).
In the present study protein drugs were released in a two-phase fashion (Figure 30
and figure 32). The initial burst release was due to the releasing of proteins absorbed
at the collagen sponge surface. The subsequent collagen sponge degradation and
protein diffusion lead to a second linear release phase and collagen mass loss.
Proteins exhibited a much more significant initial burst release from the non-cross-
linked collagen sponges since all the proteins were just admixed with collagen
sponges. While in the cross-linked collagen sponges, part of the proteins were
covalently coupled to the collagen, they are released as the collagen sponges
degradates. We suppose that it might be feasible to design a system to deliver VEGF
over a desired time span via adjusting the degradation process of collagen.
To test the release of the proteins, collagen sponges were immersed in a diluted
collagenase solution (0.04 U/ml). The collagenase solution was changed and
collected daily. As shown in our results (Figure 32), after one day, VEGF could not be
detected in the non-cross-linked collagen sponges, but VEGF could be detected in
the cross-linked group, even 10 days later.
Besides controlling the release profiles, another key issue is the preservation of
VEGF stability. As a protein, VEGF is especially fragile during formulation and
release. It is possible that VEGF may have lost its activity even before it is released
from the collagen matrices. However, the half-life of the proteins can be increased by
conjugation with inert carrier polymers (Mark Saltzman and Baldwin, 1998). We
suppose that besides changing the release kinetics, SS-PEG3400-SS cross-linking
can also prolong the biological half-life of VEGF. Ongoing investigation will focus on
the biological activity of the released VEGF.
Discussion
-79-
5.4 Cytotoxicity
The application of cross-linking agents for coupling proteins and for cross-linking
collagen implants implies that these agents exert no or little cytotoxicity. Doillon et al.
studied the tissue reaction toward activated PEGs conjugated collagen sponges. The
results showed that PEGs conjugated onto collagen sponges stabilize the porous
structure without deactivating the biological properties of collagen (Doillon et al.,
1994a). Although the safety of PEG application has been widely reported (Zalipsky,
1995) (Dittmann, 1973), the cytotoxicity and tissue response to the PEG's derivative
used in our investigations needed to be evaluated.
This was the first time SS-PEG3400-SS was used as a coupling agent in collagen
sponges , In order to evaluate the cytotoxicity of SS-PEG3400-SS we performed in
vitro tests with fibroblast cell culture and in vivo tests by subcutaneous implantation.
The effect of SS-PEG3400-SS on the proliferation of cells was investigated by
fibroblasts cultures in varying concentrations (0-10000 µg/ml) of SS-PEG3400-SS
solution. The results of MTT experiments show that SS-PEG3400-SS does not
suppress the proliferation of fibroblasts even when the concentration rises to 10000
µg/ml (Figure 33), while the concentration of SS-PEG3400-SS is only 80 µg/ml in the
protein cross-linking experiments or 400 µg/ml in in vivo exogenous collagen cross-
linking experiments.
To know the influence of exogenous collagen cross-linking on cell ingrowth behavior,
fibroblasts were seeded onto SS-PEG3400-SS cross-linked or non-cross-linked
collagen sponges. Compared with fibroblasts seeded onto non-cross-linked collagen
sponges, cells seeded onto cross-linked collagen sponges show a reasonable cell
growth and morphology (Figure 34, 35), this suggests that the exogenous cross-
linking of collagen sponges with SS-PEG3400-SS has no effect on cell ingrowth
behavior.
Before biomaterials can be applied for tissue engineering, the tissue response to
these materials has to be evaluated (Pieper et al., 1999). The presence of an
implanted biomaterial in the body will generate a series of inter-related reactions, the
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nature of which depends greatly on the type of materials and its physical and
chemical structures (Boon et al., 1995). In order to investigate the tissue responses
against the implanted materials, cross-linked or non-cross-linked collagen sponges
were implanted subcutaneously into rats, and explantations were performed 3 days,
1 week, two weeks and four weeks after implantation.
The in vivo results of the implants showed that both the SS-PEG3400-SS cross-linked
and uncross-linked collagen sponges were well tolerated by rats after subcutaneous
implantation (Figure 36-38). No intense tissue reaction was observed in both groups.
The inflammatory reaction was transitory and is clearly different from the reaction to
an irritative foreign body (Etherington et al., 1979). Two weeks after implantation,
many newly formed blood vessels had appeared in the center part of both groups of
collagen sponges with different degree of degradation (Figure 36), These results
reinforce the in vitro cytotoxicity tests, in which SS-PEG3400-SS showed no cell
growth inhibition and cell ingrowth inhibition (into collagen sponges), but a
reasonable cell growth and morphology.
Meanwhile the SS-PEG3400-SS cross-linked collagen sponges demonstrated a
significant increased resistance to in vivo degradation, which is in very good
agreement with the results of in vitro degradation. After treatment with SS-PEG3400-
SS (400 µg/ml), the collagen sponges did not collapse and kept their porous structure
for more than four weeks after implantation. In contrast, the non-treated sponges
collapsed and were gradually absorbed and replaced by collagenous connective
tissues two weeks after implantation (Figure 37,38).
The results of amino group assays and animal experiments show that cross-linking
processes already occur when the SS-PEG3400-SS concentration is lower than 40
mg/ml. This observation is not in agreement with the results of the collagenase
assay. This phenomenon may be explained by the extremely low concentration of the
proteolytic enzymes in vivo as compared with the collagenase concentration applied
in the collagenase assay.
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5.5 Conclusions
1. The homobifunctional cross-linker SS-PEG3400-SS is useful to:
- Covalently immobilize protein to collagen for controlled drug delivery. The optimal
reaction conditions for coupling HRP to collagen:
10-minute first step reaction, 1:50 molar ratio of HRP:SS-PEG 3400-SS, at pH
7.2, room temperature then stop the first step reaction via ultrafiltration.
- SS-PEG3400-SS can cross-link collagen within a short period of time, thereby
stabilize the structure and slow down its in vivo and in vitro degradation.
Increasing the cross-linker content resulted in a higher cross-linking degree.
2. SS-PEG3400-SS is not cytotoxic and can be safely used in vivo.
5.6 Future prospects
The collagen sponge is a solid 3D matrix. It may therefore take some time for the HRP-
PEG3400-SS conjugate to be distributed homogeneously into it. And also could there be
some residual air in the collagen sponge, which will hinder the contact of HRP-PEG3400-
SS conjugate with the amino groups of the collagen sponge. To solve these problems,
we have tried to perform a series of experiments in which we used soluble collagen
instead of fibril collagen. In preliminary experiment a much higher HRP coupling
efficiency (>30%) has been achieved. The possible reason may be that in solution, the
collision frequency for the HRP and SS-PEG3400-SS molecules will be much higher than
in the solid collagen sponge. Our next step is to figure out a method to incorporate this
protein-collagen conjugate into collagen sponges without harming the bioactivity of the
proteins.
Our results (RP-HPLC, MALDI-TOF) show that, in the conjugation step, relatively
high combination rates of SS-PEG3400-SS and protein can be obtained. The
combination rate of (Protein-PEG3400-SS)-conjugate with collagen, however, was still
poor. The key point of low coupling efficiency of (Protein-PEG3400-SS)-conjugate with
collagen is whether the second SS group is still active at the start of the second
reaction period.
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Two possibilities may explain the low combination rate:
1. The active –SS groups in the homobifunctional cross-linker we are using—
SS-PEG3400-SS have a very short half life of about 10 minutes. Most of them
may already have been hydrolyzed during the first reaction.
2. Both the SS groups may react with protein molecules unselectively in the
conjugation reaction. Thus it is likely to assume that, in that case no reactive
SS groups will be available for the second step reaction with amino groups of
collagen.
By using heterobifunctional PEG, this problem might be overcome. SS group still can
be used as the first functional group, because it is highly reactive and will usually not
harm the bioactivity of protein drug. The second functional group can be maleimide,
which will react with sulfhydryl groups of cysteine instead of the amine group of lysine
and remain stable in water. But as we know, there is almost no free sulfhydryl group
existing in natural collagen sponges. So we need to modify the collagen sponge by
using thiolating agents, which modify collagen by introducing free sulfhydryl groups.
In preliminary experiments a six time higher HRP coupling efficiency was observed
with the hetero-bifunctional cross-linker as compared to experiments with the homo-
bifunctional cross-linker SS-PEG3400-SS.
The extracellular matrix (ECM) is a complex structural entity surrounding and
supporting cells and is ubiquitous within mammalian tissues. Besides the soluble
molecules like growth factors, the insoluble ECM ingredients (elastin, fibrilin,
fibronectin, proteoglycans and laminin, etc) also play important roles in angiogenesis
(Ingber and Folkman, 1989). ECM may directly alter vascular endothelial cell
behavior and it may also function as a local repository for various growth factors
(Jerdan et al., 1991). An optimally engineered tissue substitute should consist of
collagen sponge plus some of these components. Experiments need to be performed
to study the effect of ECM on angiogenesis.
Our results suggest that this method of covalent linkage would also be useful for
delivering other kinds of peptide growth factors that are short-living and are important
to be kept active over a longer period of time. TGF, FGF (fibro
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blast growth factor), BMP (bone morphogenetic proteins) are some of the examples.
Since we assume that this technique only involves the functional groups on proteins,
it could be transferred from HRP and VEGF to other proteins.
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6. Summary
Introduction
Tissue engineering has been recognized in recent years as a viable solution for
repair of tissue defects. Since engineered tissues (as vascular graft) do not have
angiogenic capability by themselves, the introduction of Vascular Endothelial Growth
Factor (VEGF) could be used to enhance angiogenesis into the prosthesis tissues. A
major challenge in the development of a sustained-release of protein drugs is to
achieve a high drug loading sufficient for a prolonged therapeutic effect. To
overcome rapid diffusion and clearance from the implant site and to increase stability,
VEGF was covalently bound to collagen sponges by means of the homobifunctional
cross-linking agent bis-(succinimidyl succinate) polyethylene glycol (SS-PEG3400-SS),
after coupling activity can then be compared with control experiments in which the
VEGF was simply admixed. In order to prevent rapid degradation, collagen sponges
used as protein drug delivery substrate were cross-linked by SS-PEG3400-SS. The
biological behavior of collagen sponges as well as tissue and cell reactions after the
treatment of SS-PEG3400-SS are investigated.
Method
Protein coupling: We selected Horseradish Peroxidase (HRP) as a model protein
since it has a similar molecular weight as VEGF, and its activity can be easily
measured by spectrophotometer with high sensitivity. Covalent binding was achieved
in a two-step procedure: 1. proteins were reacted with SS-PEG3400-SS for 10 min, at
room temperature, then stop the reaction by ultrafiltration (10,000 MW, 5000 rpm),
the non-reacted SS-PEG3400-SS will be cut off; 2.the SS-PEG3400-SS attached protein
react with collagen sponge overnight at room temperature. Collagen sponge cross-
linking: collagen sponges were immersed in SS-PEG3400-SS solution for about 10
minutes, then wash extensively. Collagenase assay, fibroblast cell culture and
subcutaneous implantation were performed to evaluate the cross-linking degree and
change of biological properties of collagen sponges.
Summary
-85-
Results
1. The binding of HRP to SS-PEG3400-SS was demonstrated by reversed phase high
performance liquid chromatography (RP-HPLC), Matrix-Assisted Laser
Desorption/Ionisation Time of Flight Mass Spectrometry (MALDI-TOF-MS) and
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).
Significant higher HRP activities and VEGF antigenicity were observed when HRP
or VEGF was coupled with SS-PEG3400-SS as a comparison to control groups in
which the HRP or VEGF was simply admixed.
2. HRP or VEGF covalently coupled to collagen released in a controlled way when
the collagen sponges were degraded by collagenase.
3. The degradation of SS-PEG3400-SS cross-linked collagen sponge with
collagenase is delayed in comparison to untreated sponges.
4. In culture, fibroblasts show a normal morphology and interaction in SS-PEG3400-
SS treated collagen sponges.
5. In vivo, the porous structure of non-cross-linked collagen sponges collapse after
two weeks, but the structure of SS-PEG3400-SS cross-linked collagen sponges
remain stable and porous for more than 4 weeks.
Conclusion
1. The homobifunctional cross-linker SS-PEG3400-SS is useful to:
- covalently immobilize protein to collagen for controlled drug delivery. The optimal
reaction conditions for coupling HRP to collagen are:
10-minute first step reaction, 1:50 molar ratio of HRP:SS-PEG3400-SS, pH 7.2,
room temperature, removal excess cross-linker molecules via ultrafiltration.
- cross-link collagen within a short period of time, thereby stabilizing the structure,
and slow down its in vivo and in vitro degradation. Increasing the cross-linker
concentration resulted in a higher cross-linking degree.
2. SS-PEG3400-SS is not cytotoxic and can be safely used in vivo.
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7. Zusammenfassung
Einleitung
‘Tissue Engineering‘ bietet schon jetzt die Möglichkeit, einige Gewebedefekte
reparieren zu können. Da die künstlich gebildeten Gewebe keine angiogenen
Fähigkeiten aufweisen, könnte die Verwendung des Wachstumsfaktors VEGF
(Vascular Endothelial Growth Factor) die Angiogenese im Ersatzgewebe verbessern.
Die größte Herausforderung bei der Entwicklung eines Systems zur nachhaltigen
Freisetzung physiologisch aktiver Proteine ist die Bereitstellung ausreichender
Mengen bioaktiver Proteine für einen langanhaltenden therapeutischen Effekt. Um
eine vorzeitige Freisetzung der Proteine durch Diffusion zu verhindern, wurde VEGF
durch das bifunktionelle Reagenz bis-(Succinimidylsuccinat)-Polyethylenglykol (SS-
PEG3400 SS) kovalent an Kollagen-Schwämme gebunden, wobei durch das Reagenz
gleichzeitig die Stabilität des physiologisch aktiven Proteins erhöht wird. Die Aktivität
des kovalent gebundenen Proteins kann dann in Kontrollexperimenten mit der
Aktivität von Mischungen aus Kollagen und VEGF verglichen werden. Die für das
Protein als ‘drug delivery’ System dienenden Kollagen-Schwämme wurden durch SS-
PEG3400-SS quervernetzt, um deren rasche Degradation zu verhindern. Das
biologische Verhalten der Schwämme gegenüber Geweben und Zellen wurde
ebenfalls diskutiert.
Methoden
Protein-Kopplung: wir haben Meerrettich-Peroxidase (HRP) als Modell-Protein
verwendet, da es ein ähnliches Molekulargewicht wie VEGF aufweist und die
enzymatische Aktivität bequem photometrisch bestimmt werden kann. Die kovalente
Verknüpfung erfolgte in zwei Schritten: Die Proteine wurden mit SS-PEG3400-SS für
10 min bei Raumtemperatur zur Reaktion gebracht. Nach Ultrafiltration (10k MW,
5000 rpm) zum Entfernen des Reagenzes, werden die mit SS-PEG3400-SS
umgesetzen Proteine in einem zweiten Schritt über Nacht bei Raumtemperatur mit
Kollagen-Schwämmen zur Reaktion gebracht.
Quervernetzung der Kollagen-Schwämme: Die Schwämme wurden für 10 Minuten in
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eine SS-PEG3400-SS-Lösung eingebracht und anschließend ausgiebig gewaschen.
Um den Grad der Quervernetzung und die Veränderungen bezüglich der
physiologischen Eigenschaften zu bestimmen, wurden anschließend
Untersuchungen mit Kollagenase, Fibroblasten-Zellkultur und subkutaner
Implantation durchgeführt.
Ergebnisse
1. Die kovalente Anbindung von SS-PEG3400-SS an HRP wurde mittels
Umkehrphasen Hochleistungs Chromatographie (RP-HPLC), Matrix-Assisted Laser
Desorption Time of Flight Mass Spectrometry (MALDI-TOF-MS) und
Natriumdodecylsulfat Polyacrylamid Gel-Elektrophorese (SDS-PAGE) nachgewiesen.
Die Kollagen-Schwämme mit kovalent gebundenem Protein zeigten für HRP
photometrisch eine signifikant höhere Aktivität als die Kontroll-Gruppe mit nicht-
kovalent gebundenem Protein. Diese Ergebnisse bestätigten sich auch für VEGF
durch den Einsatz eines Enzyme Linked Immuno Sorbent Assays (ELISA).
2. Sowohl kovalent gebundenes HRP als auch kovalent gebundenes VEGF zeigten
eine kontrollierte Freisetzung bei Degradation der Schwämme durch Kollagenase.
3. Die mit SS-PEG3400-SS quervernetzten Kollagen-Schwämme wurden durch
Kollagenase im Vergleich zu unbehandelten Kollagen-Schwämmen langsamer
abgebaut.
4. Kultivierte Fibroblasten zeigten in den quervernetzen Kollagen-Schwämmen
sowohl eine normale Morphologie als auch und eine normale Interaktion.
5. Die Struktur der nicht quervernetzen Kollagen-Schwämme kollabierte in vivo
innerhalb von zwei Wochen, die Struktur der quervernetzen Kollagen-Schwämme
blieb dagegen auch nach vier Wochen noch erhalten.
Schlußfolgerung
1. Das homobifunktionelle Reagenz SS-PEG3400-SS ist geeignet für:
- die kovalente Immobilisierung von Proteinen an Kollagen und deren
anschließende kontrollierte Freisetzung. Die optimalen Reaktionsbedingungen hierfür
sind: Protein : SS-PEG3400-SS im Verhältnis 1:50, pH 7.2, Raumtemperatur. Nach 10
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Minuten wird Ultrafiltriert.
- die rasche Quervernetzung des Kollagens und somit die Stabilisierung der Struktur
der Kollagen-Schwämme (wobei eine höhere Konzentration des Reagenzes eine
höhere Quervernetzung ermöglicht). Daraus resultierend eine verlangsamte
Degradation in vitro und in vivo.
2. SS-PEG3400-SS ist nicht zytotoxisch und kann in vivo eingesetzt werden.
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9. Abbreviations
APS Ammonium Persulfate
BFGF Basic Fibroblast Growth Factor
BMP Bone Morphogenetic Protein
BSA Bovine Serum Albumin
CS Collagen Sponge
DMEM Dulbecco’s Modified Eagle Medium
DMSO Dimethylsulfoxide
ECM Extracellular Matrix
EDC N-(3-Dimethylaminopropyl)-N'-Ethylcarbodiimide
EDTA Ethylendiamin-Tetraacetate
EGF Epidermal Growth Factor
ELISA Enzyme-linked immunosorbent assay
EO Ethylene Oxide
FBS Fetal Bovine Serum
Flt-1 Fas-Like Tyrosine kinase-1
GDA Glutardialdehyde
Gly Glycine
HE Haematoxin and Eosin
HRP Horseradish peroxidase
Hyp Hydroxyproline
KDR Kinase insert Domain-containing Receptor
MALDI-TOF Matrix Assisted Laser Desorption/Ionization Time-of-Flight
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
NHS N-hydroxysuccinimide
Abbreviations
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OD Optical Density
PBS Phosphate Buffer Solution
PEG Poly Ethylene Glycol
PLGA Poly-Lactic and Glycolic Acid
Pro Proline
RP-HPLC Reversed Phase High Performance Liquid Chromatography
rhVEGF Recombinant Human Vascular Endothelial Growth Factor
SC Soluble Collagen
SDS-PAGE Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis
SS Succinimidyl Succinate
Sulfo-STDB Sulfo-Succinimidyl-4-O-(4,4`-Dimethoxytrityl) Butyrat
TEMED N,N,N',N'-Tetramethylenediamine
TFA Trifluovoacetic Acid
TGF Transforming Growth Factor
TMB Tetramethylbenzidine
Tris Tris (hydroxyethyl) aminomethane
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